Department of Endocrinology
Transcription
Department of Endocrinology
Annual Report 2009 EFE - Endocrine Research Unit Department of Endocrinology TABLE OF CONTENTS Preface.................................................................................... 4 Endocrine Research Unit Committee............................................. 5 Seven selected research stories from 2009.................................... 6 1. ROSE – Risk-stratified Osteoporosis strategy Evaluation: Providing an osteoporosis service to those at the highest risk.................... 6 2. Self-Care Behaviour Treatment in Diabetes................................ 7 3. Isolation and differentiation of Chondrocytic Cells Derived from Human Embryonic Stem Cells Using dlk1/FA1 as a Novel Surface Marker ................................................................................ 8 4. Role of Telomerase enzyme in osteoblast differentiation in vitro and bone homeostasis in vivo................................................. 9 5. Genetic Variants Involved in Mitochondrial Oxidative Metabolism are associated with Type 2 Diabetes Mellitus............................. 10 6. Clinical and immunological aspects of B-lymphocyte depletion with rituximab in Graves´ disease........................................... 11 7. Patient education on retinopathy ............................................. 12 The Danish PhD School of Endocrinology....................................... 14 The Danish PhD School of Molecular Metabolism............................ 14 Current PhD projects carried out in EFE........................................ The Bone and Calcium Research Group.................................... The Diabetes Research Group................................................. The Molecular Endocrinology Unit (KMEB)................................. The Pituitary- and Clinical Nutrition Research Group................... The Thyroid Research Group................................................... The Clinical Nursing Research Group........................................ 15 15 15 17 18 19 19 Researchers and technical/administrative staff in EFE - as per 31 December 2009......................................................... The Bone and Calcium Research Group.................................... Clinical Nursing Research Group.............................................. The Diabetes Research Group................................................. The Molecular Endocrinology Unit (KMEB)................................. The Pituitary- and Clinical Nutrition Research Group................... The Thyroid Research Group................................................... 20 20 20 20 21 22 22 Completed PhD theses............................................................... 23 Publications.............................................................................. 24 Financial support to EFE ............................................................. 30 3 PREFACE Our goal is diagnostic treatment based on scientific knowledge, and therefore it is my pleasure to ascertain the high number of medical publications – more than 100 this year. It is also a pleasure to congratulate the 7 ph.d. students who finished their training and obtained their ph.d. degree. The research stories presented here are showing that department M is producing interesting results which can be implemented in the clinical work for the benefit of patients. By Professor, Dr. MSci. Henning Beck-Nielsen Research Manager EFE In 2009 Torben Hansen, Hagedorn Research Institute, was appointed adjungated professor at EFE. A warm welcome to Torben. Indeed, we want to thank everybody who has contributed to our research, specifically all the patients who agreed to be at the disposal for science. The same gratefulness applies to all the health control subjects. I hope that this annual report shows all of you that it was worth it. I also want to extend my thanks to all staff, both those who are directly involved in research and those who in their clinical work enables research to thrive. Endocrinology Research Unit (EFE) is a venture of all research efforts around endocrinology concentrated at department of Endocrinology M, Odense University Hospital. EFE has its own research lab – clinic for Molecular Endocrinology and Endocrinlogy Treatment (KMEB) and presently, 23 Ph.d. students are trained in EFE. EFE also embraces two PhD Schools in which a close collaboration between the faculty of Natural Science and Technology of University of Southern Denmark and the Panum Institute of University of Copenhagen is taking place. A special thank to our research secetaries, who through their daily work secure a smooth work flow, and who have produced this annual report: Nanett Mosumgaard, Tine Hylle, Tina Barbisan Hansen, Kristine Michailidis and Sandra Harris. Also a warm thank to the Faculty of Health Science, the hospital management and to the foundations for their support to the research activites in endocrinological research. 4 ENDOCRINE RESEARCH UNIT COMITTEE Marianne Andersen Consultant, PhD The Pituitary Gland Resarch Group Henning Beck-Nielsen Professor, Consultant, DMSc Chairman The Diabetes Research Group Kim Brixen Professor, Consultant, DMSc The Bone and Calcium Research Group Rene Støving Consultant, PhD The Pituitary- and Clinical Nutrition Research Group Laszlo Hegedüs Professor, Consultant, DMSc The Thyroid Research Group Moustapha Kassem Professor, Consultant, DMSc The Molecular Endocrinology Unit (KMEB) Anne Holm Nyland Development Nurse, MSc in nursing Clinical Nursing Research Group Dorthe Nielsen Nurse, RN, MHS, PhD The Bone and Calcium Research Group Nanett Mosumgaard Research Secretary 5 SEVEN SELECTED RESEARCH STORIES FROM 2009 - examples of EFE research areas 1 is based on a few simple questions such as “do you smoke?”, “did your mother or father have osteoporosis?” and data on height, weight and age of the patient. This tool may allow us to offer DEXA to high-risk patients with better precision. This is the basic idea of the study. ROSE – Risk-stratified Osteoporosis strategy Evaluation: Providing an osteoporosis service to those at the highest risk by Katrine Hass Rubin; PT, MHS and PhD-student; The Bone and Calcium Metabolic Research Group Randomized design is necessary The primary aim of the project is to test if risk-stratified screening for osteoporosis in women aged 65-80 years is effective in preventing fractures. In order to obtain solid data on this issue, the study is randomized, i.e. 50% of the participants will be “controls” and 50% will be “screened”. A total of 15,000 women aged 65-80 years are selected at random from the Central Person Register and randomized. All the women will receive the “FRAX questionnaire” and women in the screening group with a 10-year probability of major osteoporotic fracture above 15% are invited to a DEXA-scan. If osteoporosis is diagnosed, treatment and follow-up will be carried out in general practice. While the main question is whether or not this new strategy is effective, a number of associated questions will also be clarified – if the screening program is cost-effective and the women’s attitudes, experience and acceptance of the screening program. Moreover, a second part of the study will investigate the use of ultrasound machines in the assessment of osteoporosis. This part of the study is scheduled to start in the autumn of 2010. In January 2010, we have started inclusion of women in a large-scale trial on risk-stratified screening for osteoporosis (ROSE). This study will – as one of the first in the world – investigate the effect of a screening program for osteoporosis in postmenopausal women in a randomized design. The study will include 15,000 women in the Region of Southern Denmark. The study is supported by the Region of Southern Denmark and INTERREG and is performed in collaboration between researchers in Esbjerg, Kolding, Odense and Kiel. Osteoporosis is under-diagnosed Osteoporosis is highly prevalent especially in postmenopausal women and grave consequences for those patients suffering e.g. hip fractures. Moreover, the costs to society that results from treatment and care of fracture patients are enormous. Indeed, approximately 45% of all women will suffer at least one fracture during their lifetime where osteoporosis is a causal factor. In Denmark as in many other countries, a case-finding strategy is currently used to identify patients with possible osteoporosis. Ideally, women with one or more risk factors should be referred to a DEXA-scan by their general practitioner. This strategy, however, seems to result in referral of only few high-risk patients while many resources are used to examine women with relatively low fracture risk. Recently, the WHO Collaborating Centre for Metabolic Bone Diseases at Sheffield developed the Fracture Risk Assessment Tool (FRAX®) to improve the case-finding strategy and help general practitioners in their daily praxis to calculate the individual risk of fracture in women and men in order to identify the patients at highest risk of fracture. FRAX uses clinical risk factors to predict the 10-year risk of hip fractures and other fractures in individual patients. Calculation of FRAX Regional and cross-boarder collaboration The project is performed in close international collaboration between Odense University Hospital, Kolding hospital, Hospital of South Western Jutland (Esbjerg), University of Southern Denmark and Kiel University Hospital. Moreover, four PhD–students (or PhD-students-to-be) are currently working on the study; Mette Rothmann, Teresa Holmberg, Mikkel Høiberg and Katrine Hass Rubin. The ROSE study will include women in the next 1-2 years. Duration of the study is anticipated to be 3-6 years depending on e.g. participation rate. The large amount of data from the project will be analyzed by 4-8 PhD-students during the years to come. 6 2 Self-Care Behaviour Treatment in Diabetes improvements in long-term glycaemic control and to establish the most effective regime. by Lisbeth Minet, Else-Marie Lønvig, Lis Wagner, Jan Erik Henriksen, the Diabetes Research Group Aim and Methods The aim of this randomised controlled trial was to study the effect of a 1 year nurse-led intervention programme based on Motivational Interviewing describe by Miller and Rollnick in patients diagnosed with diabetes type 1 DM or type 2 DM. Our approach was derived from Albert Bandura’s Selfefficacy theory of human intentional acts through their beliefs in their capability to perform a desired effect by their actions. All 349 participants included in the trial received a four days diabetes education programme before randomisation to an intervention group or a control group. After the education programme both the intervention and control group were discharged to usual care consisting of visits to their physician every three months. In addition to usual care the intervention group received five individual sessions in one year given by diabetes specialist nurses educated in Motivational Interviewing. The goal of intervention was to help patient to recognise and address problem areas in the diabetes self-management. By request the patients in the intervention group were referred to a tailored counselling in changes of diet, smoking habit, physical activity and alcohol use. All data are collected prospectively over the period of 5 years. Figure 2 illustrate the participants flow throughout the trial. Background The large amount of research in the self-management area testifies to the urgency this factor is given in the diabetes treatment. Self-management of diabetes involves a number of considerations and choices that each patient with diabetes takes on a daily basis. It requires that patients are able to reconcile their resources, values and preferences with a therapeutic regimen of healthy diet, exercise, no smoking, low alcohol intake, glucose monitoring and for some medication. The knowledge of how self-management evolves in the lives of patient with diabetes is stressed to be essential in the organization of treatment approaches. This means that there has been an increased focus on patient responsibility, as clarified in the attempts to encourage patients to be active participants in the diabetes treatment and thereby enabling the patients to control their diabetes. However, the ability to handle the daily care of diabetes steel seems to be a challenging task for many patients with diabetes. A patient’s ability to be involved in the daily routine of diabetes care seems to be grounded in psychological and motivational factors as well as educational factors. The inability to conduct selfmanagement activities and to assume responsibility for daily diabetes care is reflected in poor outcomes, which makes the patients more prone to diabetes-related complications such as blindness, kidney damage, amputation of lower limbs and cardio vascular illnesses. Therefore, in research purposes, it has been of interest to find ways to strengthen the individual’s belief and competence to handle their diabetes. Results The findings from the qualitative data collection method indicated the need for involving patients in setting the objective of therapy to ensure for the patient a meaningful and applicable treatment that can be transferred to various everyday situations. It was suggested that people with diabetes have specific needs for support in the daily responsibility of managing the rules of conduct within diet, exercise, blood glucose monitoring, and medication intake. Health care professionals should be aware of the difficulties for some vulnerable patients to handle the responsibility of self-management. The assessments of quantitative data are ongoing. Results are expected to be presented June 2010. A meta-analysis of 47 randomised controlled trials was carried out to establish knowledge about the existing evidence on the effectiveness of selfmanagement intervention on diabetic control. The analysis found improvements in glycaemic control indexed by glycated haemoglobin with a 0.358 % decrease in HbA1c (95% CI -0.509 to -0.207) in diabetes patients who received self-care behavioural intervention compared to a control group. This was especially true under conditions which imply an intense and individual treatment. However, further research is needed to establish knowledge about 7 Figure 2 3 Isolation and differentiation of Chondrocytic Cells Derived from Human Embryonic Stem Cells Using dlk1/FA1 as a Novel Surface Marker Aim and methods We aimed in this study to design a clinically relevant protocol for directing the differentiation of hESC into chondrocytes based on tracking the dlk1/FA1 expression as a novel mesoderm/chondroprogenitor surface marker. hESC were differentiated as human embryoid bodies (hEBs) in 3D culture for 10 days in the presence of 50 ng/ml Activin B. FACS cell sorting was employed to isolate dlk1/FA1+ cells from Activin B-induced EB-outgrowth culture in serum free medium. hESC-derived dlk1/FA1+ cells were induced to differentiation into chondrocytes by culturing them as a micromass pellets in the presence of 10 ng/ml TGFβ1. By Basem M. Abdallah, Lektor. The molecular Endocrinology Unit (KMEB) Human embryonic stem cells are considered as a good source for providing differentiated cells for cell-based therapy of cartilage degenerative diseases including osteoarthritis and traumatic cartilage injury. However, chondrogenic differentiation protocols for hESC have limited success and have been mainly accomplished via co-culture conditions or adding exogenous extracellular proteins. In order to develop well-defined and efficient protocols for directing hESC differentiation into chondrogenic lineage in vitro, there is a need to identify novel surface markers that define early stages of hESC commitment to chondrocytes. Delta-like1/ fetal antigen1 (dlk1/FA1) is a transmembrane protein of the Notch/Delta/Serrata family. Here, we identified dlk1/FA1 as a novel surface marker for chondroprogenitor cells that undergoing transition from proliferating to prehypertrophic chondrocytes in parallel with the expression of Sox 9 and type IIA procollagen during mouse limb bone development (Figure 1). The same pattern of dlk1/FA1 expression was also obtained in hESC-derived cartilage in vivo (Figure 2, upper panel). Results We employed dlk1/FA1 as a surface marker to identify mesodermal/chondroprogenitor cells during human embryonic stem cell (hESC) differentiation. FACS analysis, immunohistochemistry and real time-PCR showed an association between dlk1/FA1 expression and the up-regulation of mesoderm specific markers during in vitro differentiation of hESC into embryoid bodies (Ebs). Activation of TGFb emodellin in hEBs outgrowth culture using Active B markedly induced mesoderm lineage in parallel with up-regulating Dlk1 expression. Thus, we used FACS cell sorting to enrich for mesoderm/dlk1/FA1+ cells. Interestingly, hESC-derived dlk1+cells showed to differentiate efficiently into a pure population of chondrocytic cells when cultured as micromass pellets in a xeno-free system containing TGFβ1 (Figure 2) Figure 1 Figure 2 8 4 Role of Telomerase enzyme in osteoblast differentiation in vitro and bone homeostasis in vivo AG, Zürich, Switzerland) scanned bone samples for the region of interest that is trabecular and cortical bone of proximal tibia. Bone marrow cells were harvested according to the protocol described by Peister, with some in house modifications. By Hamid Saeed, B.Pharm, Mphil, PhD student, the Molecular Endocrinology Unit (KMEB) Results Whole skeletal mount staining of E17.5 days old embryos revealed mild patterning defects with delayed ossification in occipital bone, calvarial sutures, sternubra, metatarsal and caudal vertebrae (Fig.1A). TERC-/- exhibited accelerated agerelated bone loss starting at 3 months of age and during 12 months follow up period as evidenced by, DEXA (Fig. 1C) and µ-CT trabecular bone volume (TBV/TV) in TERC-/- 0.078 ± 0.020 vs wild type mice (WT) 0.113 ± 0.029 (p< 0.05, n=6)(Fig. 1D). Stromal (mesenchymal) stem cells (MSC) isolated from TERC-/- mice exhibited intrinsic defects with reduced total number of CFU-F and alkaline phosphatase positive (AP+)-CFU-F (Fig.1E) Introdcution Osteoporosis is a multifactorial and complex disorder characterized by bone fragility and increased risk for fractures. One of the principal pathophysiological mechanisms underlying osteoporosis is the impairment of osteoblastic bone formation during bone emodelling with aging. In this context, we have previously demonstrated that age-related and osteoporosis-related impairment of bone formation is caused by accumulation of senescent osteogenic stem cells that impairs bone regeneration capacity, though; self-renewal capacity of hMSC could be restored by over-expression the hTERT gene in hMSC thereby enhancing proliferation and in vivo bone formation capacity. However, in vivo consequences of defective telomerase activity and shortened telomere on bone stem cells and bone biology are poorly studied. Conclusion Our data demonstrate that telomerase plays an important role in maintenance of stem cell functions and activation of telomerase in MSC or in a compartment specific manner can be a novel strategy for abolishing age-related bone loss. Objective The aim of this project is to determine the physiological role of telomerase in osteogenic stem cell proliferation and differentiation to osteoblastic cells and also its effects on bone homeostasis in vivo using the TERC knockout mouse model that lacking telomerase activity due to null mutation in RNA component of telomerase complex. Methods 17.5day old embryos were de-skinned and eviscerated. Staining was performed in a solution of 90% ethanol, 5% acetic acid, and 5% H2O supplemented with 0.005% alizarin red S (Sigma) and 0.015% alcian blue 8GS (Sigma) for 3 days at 37°C. Total body mass (grams) bone mineral content (milligrams) and bone mineral density (milligrams per square centimetre) were measured using DEXA scanner. μCT scanner (viva-CT 40, Scanco Medical 9 5 Genetic Variants Involved in Mitochondrial Oxidative Metabolism are associated with Type 2 Diabetes Mellitus Exploring results from a meta-analysis of genome wide association studies (DIAGRAM Consortium), we found that among 1284 SNPs in 119 OxPhos genes, 39 SNPs showed potential association with T2D (uncorrected p<0.01). SNPs that were in linkage disequilibrium (r2>0.8) were excluded from further analysis. The resulting 10 SNPs in or near 6 OxPhos genes were genotyped in 3,139 T2D patients and 5,302 controls with normal glucose tolerance. By Lena Soender Snogdal, Md, PhD student, the diabetes research group Introduction Type 2 diabetes (T2D) is the most common form of diabetes and a dramatic increase in prevalence is being observed worldwide. Like T2D, obesity is an increasing problem in the Western World and has taken on epidemic proportions. T2D and obesity is in part inherited and therefore a lot of research focuses on finding genetic factors contributing to the diseases. T2D is characterized by insulin resistance (IR) and failure of the pancreatic beta cells to compensate for this defect. Several studies have demonstrated a link between IR and impaired mitochondrial oxidative phosphorylation (OxPhos) in skeletal muscle. Oxphos consists of respiratory chain and ATP synthesis (shown in the figure). Recently, mitochondrial defects have also been implicated in beta-cell dysfunction in T2D. Results Rs1466100 in COX5B (OR=1.67, p=0.004) and rs9915302 in COX10 (OR=1.14, p=0.02) were significantly associated with T2D. In a meta-analysis combining our results with data from an available subset of the DIAGRAM data, we demonstrated that three SNPs (rs10775377, rs8077302, rs9915302) in COX10 and a SNP (rs2267584) in a gene (UPK1A) next to COX6B1 were significantly associated with T2D. In particular, the rs9915302 variant in COX10 showed strong association with T2D (OR=1.14, p=7.7x10-6). Analysis of quantitative traits, applying an additive model and adjusting for age and sex, revealed significant associations (p<0.05) between a surrogate marker (BIGAIR) of insulin secretion and variants in COX5B (rs11904110) and COX10 (rs10521253), between fasting plasma glucose and rs11904110 in COX5B, and 2-h post-OGTT plasma glucose and rs8134542 in NDUFV3 (p<0.05). Aim and methods The overall aim of this thesis is to contribute to the pathological exploration of the genetic risk factors of T2D with a special focus on mitochondrial dysfunction by genotyping selected single nucleotide polymorphisms (SNPs). All SNPs have their own specific rs-number and are specified by which gene hey are placed in or near by. DNA string Conclusion Our data suggest that genetic variants in or near genes encoding subunits in complex IV (COX5B, COX6B1, COX10) contribute to the pathogenesis of T2D. The observed association of variants in COX5B, COX10 and NDUFV3, with markers of insulin secretion and postprandial hyperglycaemia, supports a role for mitochondrial defects in betacell dysfunction in T2D. In this specific study we hypothesized that single nucleotide polymorphisms (SNPs) in OxPhos genes could contribute to the pathogenesis of T2D. 10 6 Clinical and immunological aspects of B-lymphocyte depletion with rituximab in Graves´ disease ly in the RTX-treated patients. These results support the case that methimazole therapy does not affect the autoimmune process per se. The specific declines in a subset of autoantibodies may rely upon the need for intrathyroidal germinal centers for their production, or the preferential production of these autoantibodies by short-lived plasma cells. As to the former argument we showed that B cells were absent from the thyroid 7 days after RTX therapy 4. Two patients included in the study had active, previously treatment refractory GO, both patients showed a marked improvement in GO severity as well as activity 5. Unanticipated from literature review, RTX induced articular and gastrointestinal adverse events in three and two of the patients, respectively. In conclusion, RTX seems to have some efficacy in GD. However, side effects and high cost disfavours the use in GD without GO. In our hands, RTX seemed effective in GO. This finding has been confirmed in other small patient series, and is presently under investigation in randomized placebo-controlled trials. By Daniel El Fassi, MD, the Thyroid Research Unit Graves´ disease (GD) is an autoantibody-mediated autoimmune disease, which has a prevalence of around 1-2%. The hyperthyroidism affects various organ systems, and has a marked impact on quality-of-life. Only around half of the patients achieve remission by an initial 12-18 months course of antithyroid drugs 1. The remaining half of the patients often require thyroidectomy or radioiodine treatment, both of which infer a risk of permanent hypothyroidsm. Marked Graves´ ophthalmopathy (GO) is present in 5-10% of the patients. The pathogenesis of GO is less clear than that of GD. The mainstay of current therapy is high-dose glucocorticoid therapy, with retrobulbar irradiation or orbital surgery as the second-line alternatives. Treatment responses are often unsatisfactory in GO patients, and particularly in this condition, novel treatment modalities are warranted. We have conducted a controlled but non-randomized and non-blinded study with the main focus on evaluating the efficacy and safety of the B-lymphocyte depleting agent rituximab (RTX) in GD. Furthermore, we wished to evaluate immunological changes occurring after the treatment 2. We rendered 20 patients with GD euthyroid using standard methimazole therapy given for around four months, the last four weeks of which ten of the patients received weekly infusions of RTX 2. At the end of follow-up, which was at least one year, four RTX-treated patients remained euthyroid, while all the non-RTX treated patients had relapsed. All the patients who maintained euthyroidism had low baseline TSH-receptor antibody (TRAb) levels. Upon relapse methimazole therapy was reinitiated. We were able to evaluate precisely the changes in autoantibody levels attributable to RTX therapy (Figure). TRAb levels declined in both groups with no difference between the treatment groups. However, using a bioassay involving Chinese hamster ovary cells transfected with the human TSH-receptor the stimulatory activity of the TRAbs (TSAb activity) decreased markedly and specifically in RTX-treated compared to non-RTX treated patients 3. Thyroid peroxidase antibody levels also declined specifical- Legend Antibody levels following treatment with 375 mg/ m2 rituximab at days 1,8,15 and 22 in ten patients with Graves´ disease who also received methimazole. Mean values±SEM are shown on a logarithmic scale. A matched control group received methimazole only. Immunoglubulin (Ig) G and TRAb levels were not differentially affected by RTX (open symbols). IgM levels, thyroid peroxidase antibody (TPOAb) levels, and the biological activity of the TRAbs (TSAb) were differentially affected (filled symbols). In the control group, TPOAb and TSAb levels were unchanged over time, and IgM levels increased slightly (data not shown). The dotted line represents the theoretical half-life of IgGs, the Ig subtype to which most TRAbs, TSAbs and TPOAbs belong. 11 7 Patient education nopathy on reti- For evaluation height, weight and blood pressure was measured. Blood samples were drawn (HbA1c, low density lipoprotein, high density lipoprotein, total cholesterol and triglycerides). Retinal photography was obtained. Thirty-seven completed the study. Primary endpoints of the study were to test the effect of the program on parameters of lifestyle changes and self-efficacy. Secondary endpoint was to test the effect of the program on progression in retinopathy. Primary endpoints were tested by applying T-test on delta-values in the two groups. No differences over all between the two groups were found. The secondary endpoint was change in the degree of retinopathy. There were no significant differences between the groups. Data did not involve the possibility that a patient could have worsening at one eye, and at the same time improved on the other eye. To comply with this a score system was made to find the overall changes in retinopathy (figure 1). Overall both groups improved. By Rothmann M, Nyland A.H, Hammelsvang L, Petersen L, Kirketerp G, Henriksen J.E. Retinopathy is a common complication of diabetes. A fourth of the patients with type 2 diabetes have retinal micro vascular changes at time of diagnoses (1). Furthermore, many patients with type 1 diabetes will develop retinopathy during to the disease duration (2). The aim of the present study was to evaluate a new nursing practice for diabetic patients with retinopathy. We wanted to determine if systematic patient education could optimize knowledge of retinopathies, lifestyle changes and self management. Furthermore, to evaluate if the acquired patient knowledge and capabilities could prevent retinopathy progression and ultimately save eye-sight. Fifty patients were randomized to either an intensified educational program or the standard follow-up procedures in the outpatient clinic. The study period was two years with evaluation at baseline, after 12 and 24 months whereas focus group interviews were performed at 12 month only. The educational program applied to the intervention group contained 4 lessons of 1½ hours during a three months period (table 1). Teaching methods were inspired by Aron Antonovskys ‘sense of coherence’ and an approach on empowerment. Patient’s experiences were central in an attempt to strength self-management (3,4). Teaching was seen as a pluralistic approach on evidence based practice (5,6). Figur 1 The control group The intervention group Table 1 P.M. Lesson 1 (week 1) Lesson 2 (week 2) Lesson 3 (week 3) Lesson 4 (week 7) 2.30-3.15 Introduction, Expectations of Education Prevention of Retinopathy Treatment of Retinopathy Everyday life and Retinopathy 3.15-3.30 Break Break Break Break 3.30-4.15 Anatomy and Physiology of the eye Prevention of Retinopathy and Self-care Treatment of Retinopathy, Cataract, Glaucoma and Age-related Macular Degeneration Closing discussion The themes found in the focus group interviews were nearly identical, but the weighting and description of the themes were different (figure 2). Fear of blindness was the only theme described identical at the time of diagnosis. The main theme in the two groups differed. “Knowledge” was the most significant theme in the intervention group. Knowledge on retinopathy was described as important in everyday life, indicated as 12 Figur 2 ned. In contrast the intervention group took responsibility in the prevention showed as shared care. The study has illustrated the need for patient education in relation to retinopathy and the need for constantly developing new nursing practices to support the patients. The interviews findings confirm that knowledge on diabetes and retinopathy as well as openness to the psychological dimension of retinopathy strengthens the patient sense of coherence resulting in less fear or anxieties (7). Moreover, the interviews findings illustrated that knowledge on retinopathy, self-care, and self-efficacy in relation to retinopathy are associated to responsibility and motivation to prevention of diabetic complications. Contrary our quantitative data did not show any significant effect of the education program. Education had a positive effect on sense of coherence, empowerment, self-care and self-efficacy in relation to responsibility, ownership and everyday life with diabetes and retinopathy. The main point in this study might be that knowledge achieved by patient education seems to be comprehensible and meaningful. Knowledge is turned into everyday life. motivation for metabolic control. The main theme in the control group was “Responsibility for prevention”. Responsibility should be handled by professionals and they themselves had only a minimum of responsibility for the prevention. The control group indicated knowledge on retinopathy, but did not act according to the knowledge. The patients felt safe, but it did not reduce their fear of blindness. Both groups described “accept”. Characteristic of the two groups were that the control group was resig- at KMEB Lab 13 THE DANISH PHD SCHOOL OF ENDOCRINOLOGY www.endocrinology-phd.dk • To intensify the efforts of the involved instituti ons (Nordic Bioscience and the University of Sou thern Denmark) to educate PhD candidates with a solid background in medical endocrinology. • To build up a national and international network between leading researchers in the field of medi cal endocrinology. • To build up a national and international network between leading researchers in the field of me dical endocrinology. Background The Danish PhD School of Endocrinology is a new PhD school established on 1 August 2008 and financed by the University of Southern Denmark and Nordic Bioscience A/S, Center for Clinical and Basic Research. The main research areas of the school are application-oriented clinical endocrinology. The disease areas include calcium metabolic diseases, diabetes mellitus, metabolic syndrome, obesity, cardiovascular risk factors and fibrosis. PhD students The school has now enrolled the first 8 PhD students. PhD Courses and Curriculum The head of the PhD school is Professor Henning Beck-Nielsen, Dept. of Endocrinology, Odense University Hospital. A coordination committee is responsible for proposal and approval of PhD projects and PhD students. The aims of the PhD School of Endocrinology are: • To establish a high-standard, international PhD programme in medical endocrinology with spe cial emphasis on metabolic diseases with incre ased tissue turnover, such as osteoporosis, oste oarthritis, cardiovascular diseases and fibrosis. THE DANISH PHD SCHOOL OF MOLECULAR METABOLISM www.metabolism-phd.dk laborates with a large number of well-estimated researchers and private companies both nationally and internationally. Background The Danish PhD School of Molecular Metabolism is a joint venture between the Faculty of Science and the Faculty of Health Sciences at the University of Southern Denmark and the Faculty of Health Sciences, University of Copenhagen. The Danish PhD School of Molecular Metabolism is organised with a head, a board, an international Advisory Board (approx. 20 members) and a national Faculty (approx. 45 members). Chief consultant, professor, MD, DMSc Henning Beck-Nielsen is head of the Danish PhD School of Molecular Metabolism. Aims • To train PhD students in theoretic and practical methods in the field of molecular metabolism, i.e. genomics, transcriptomics, proteomics, li pidomics, metabolomics and bioinformatics. • To train PhD students in using these methods in the field of cell biology and for clinical applicati on, especially in relation to type 2 diabetes, obesity and the metabolic syndrome. • To stimulate ”translational research” by assu ring that more PhD projects stretch from ”mole cule to sick bed” • To organise a core curriculum covering the abo ve spectrum. • To strengthen the cooperation between univer sity research, public sector research and indu strial research. • To build up a national and international network between leading researchers in the field of mo lecular metabolism. The School is interdisciplinary and research-focused and employs new cellular methods for the study of molecular metabolism, especially in connection with diseases in glucose and fat metabolism, i.e. obesity and type 2 diabetes. The school integrates the entire metabolic spectrum from genome through transcriptome and proteome to metabolome. The tehcniques are applied to large, well-defined cohorts (epidemiology) and clinically representative patient groups (diseases). The PhD school covers subject areas such as genetics, physiology, biochemistry, molecular biology, endocrinology and diabetology. The PhD school col- PhD students In total the Danish PhD School of Molecular Metabolism has 60 PhD students enrolled. 14 CURRENT PHD PROJECTS The Bone and Calcium Research Group BMD decrease is seen, with a subsequent small increase or return to baseline. Still, both the number of vertebral and peripheral fractures is reduced by approx. 60%. HR-pQCT is a newly introduced imaging technique to assess density and micro-architectural morphology of the radius and tibia offering an evaluation of bone quality potentially superior to DXA, which could possibly capture changes in bone morphology underlying the above results. However, HR-pQCT is yet an unproven technique with the need for further validation. Dorthe Nielsen, RN, MHS The Importance of Patient Education in Groups in Patients with Osteoporosis - A qualitative and quantitative project. In this study, we aim to understand the influence of patient education in relation to patients’ way of coping with osteoporosis in the conduct of every day life. The first part of the study is a randomised controlled trial, here we hypothesise that multi-disciplinary education of patients with osteoporosis increases compliance, physical activity and knowledge on osteoporosis. In part two focus groups are being completed with 4x6 men diagnosed with osteoporosis, to get the gender perspective. In the last part of the study 20 qualitative interviews are being performed in Odense University Hospital, DK and Nottingham University Hospital, UK). Focus is held on similarities and differences for patients’ possibilities to act in concrete contexts. Katrine Hass Rubin, MT, PHS Risk stratified screening for osteoporosis in the Region of Southern Denmark The aim of this study is to evaluate whether risk stratified screening with one of the existing fracture risk tools (FRAX, OST, SCORE, ORAI ORISIS, OPERA) is an effective methods to identify post menopausal women with increased fracture risk. The study was designed as a population-based crosssectional study where 5,000 women, aged 40-90 years, living in the region of Southern Denmark, were mailed a self-administered questionnaire concerning risk factors for osteoporosis. The respondent rate was 84 %. Following studies will be done on the data; Describing the prevalence of risk factors and the use of DXA-scanning, Validate FRAX in a Danish population, investigate the correspondence between and the existing fracture risk tools, evaluate their predictive values. Morten Frost Nielsen, MD SOMA – Study on Male Osteoporosis and Aging Osteoporosis and fractures in men are a significant public health problem. The disease is a very heterogeneous clinical entity: some develop osteoporosis in a relatively young age for idiopathic reasons while others may have secondary causes. Some 10.000 men aged 60-75 received a questionnaire by mail in 2004. The questionnaire was designed to capture potential factors that could be related to the development of osteoporosis or increase fracture risk. Respondent were all enrolled in a nested case-control study of causes of fragility fractures in men. In cases as well as controls, BMD, hormonal status etc are evaluated. The study is expected to improve our knowledge on male osteoporosis including in particular risk factors for fragility fractures. The Diabetes Research Group Lisbeth Minet, Physiotherapist, MHS Self-care behaviour treatment in patients with type 2 diabetes The aim of the project is to study the long-term effect of a motivational intervention program based on cognitive-behavioural strategies in patients with diabetes. A randomized controlled trial with 400 patients with type 2 diabetes is carried out at an endocrinology unit. The sample size was determined by a power calculation based on a standard deviation of 1.15 in the HbA1c-value and a 5% two-sided significance level. The power is set to 90 %. Assessments are made at baseline, follow-up 1 year and follow-up 2 year. Statistical analysis will be used to compare end points between the two groups.The effect will be evaluated on both physiological and psychosocial parameters. Stinus Hansen, MD The effects of parathyroid hormone on bone structure assessed by high-resolution peripheral quantitative computed tomography (HR-pQCT) Parathyroid hormone (PTH) is a key hormone in bone remodeling with either catabolic or anabolic actions depending on exposure. The continuously elevated PTH in primary hyperparathyroidism (PHPT) increased bone turn over, the risk of fracture and decreases bone mineral density (BMD) in both the spine and peripheral skeleton when measured with dual energy absorptiometry (DXA). As opposed to this 18 month of treatment with once daily biosynthetic PTH injections in patients with osteoporosis, increases spine BMD by approx. 10% whereas in the hip and forearm an initial Birgitte Vind, MD Studies of molecular mechanisms behind insulin resistance in type 2 diabetes The ph.d. study comprises two different projects which address the pathogenetic features behind insulin resistance 15 and glucose metabolism in type 2 diabetes from different angles. In the first project glucose metabolism is examined by means of a hyperinsulinemic clamp at euglycemic and hyperglycemic conditions respectively in order to evaluate the effect of glycemia on the activities of relevant intramyocellular enzymes. In the second project the effect of training on insulin resistance and selected metabolic parameters is evaluated in a group of type 2 diabetic subjects compared with obese controls. Material and methods: 360 obese women with BMI> 30 are randomised to lifestyle intervention (n=180) or control group (n=180). The intervention is composed of individual dietarian counselling and physical training. The physical training includes weekly aerobic lessons in a fitness centre and coaching in small groups. Both groups will be examined during pregnancy with extra ultrasound scanning of the fetus and measuring of weight, blood pressure, and metabolic markers. Lena Sønder Snogdal, MD Genetic Variants and Phenotypic Characteristics of Patients with Type 2 Diabetes Mellitus Xiaolu Zhao, MSc Mass spectrometry-based quantitative proteomics in the study of mitochondrial dysfunction in muscle in type 2 diabetes The aim of this PhD study is to get a further insight in the field of Type 2 Diabetes (T2D) and genetics. T2D is a disease of worldwide increasing incidence and prevalence. It is caused both by genetic and environmental factors. There is an ongoing intensive research in the genetic field. Hopefully this work can add new knowledge into this field. Therefore the project consists of several arms: 1. Collecting DNA and clinical data from a cohort of T2D patients and non-diabetic controls in Odense 2. A candidate gene study of genes related to mitochondrial dysfunction and oxidative phosphorylation in DNA from existing cohorts from Odense and Steno Diabetes Center 3. A second candidate gene study of genes related to lipid droplets on existing cohorts from Odense and Steno Diabetes Center and on my own cohort 4. A third study of genes already associated to T2D in a specific group of patients from Odense who has previously been examined by hyperinsulinaemic clamps on muscle biopsies. Mitochondria are the primary energy-generating systems in eukaryotes. They play a crucial role in oxidative metabolism including carbohydrate metabolism, fatty acid oxidation and urea cycle, as well as in calcium signaling and apoptosis. Mitochondria dysfunction is centrally involved in a number of human pathologies, such as type 2 diabetes (T2D). Abnormalities in mitochondrial oxidative phosphorylation (OXPHOS) activity are believed to contribute to fat accumulation and insulin resistance in skeletal muscle of patients with T2D. To which extent this is caused by post-translational modifications (PTMs) of OXPHOS proteins remains undetermined. Mass spectrometry-based proteomic analysis is a powerful tool for global profiling and quantification of proteins and their PTMs. Therefore, the aim of this project is to establish methods for application of mass spectrometry -based quantitative proteomics and phosphoproteomics in mitochondria isolated from human skeletal muscle biopsies, and apply these methods in identifying OXPHOS proteins with altered expression and/or phosphorylation in muscle mitochondria from patients with T2D. Christina Anne Vinter, MD LIFESTYLE AND PREGNANCY: The clinical effect of lifestyle intervention during pregnancy in obese women Steffen Bak, MD Phosphoproteomic characterisation of mitochondrial dysfunction and insulin resistance in type 2 diabetes. From molecule to diabetes Aims 1. To study the effects of diet and physical training during pregnancy among Danish obese women. Primary outcomes: Rate of caesarean section, gestational diabetes mellitus, hypertension/preeclampsia, LGA, and admission to neonatal intensive care unit. 2. To describe the metabolic effects of lifestyle intervention during pregnancy. Background: Obesity in pregnancy is related to higher maternal morbidity and perinatal morbidity and mortality. The risk of gestational diabetes, hypertensive complications, caesarean section, induction of labour, and children born large for gestational age (LGA) is increased with increasing maternal BMI. The central hypothesis of this project is that reversible phosphorylation of mitochondrial proteins contributes to the regulation of a number of mitochondrial processes, and that abnormalities in this regulation play a role for the link between mitochondrial dysfunction and IR. Such abnormalities could be due to altered signaling to mitochondrial phosphoproteins in response to insulin and acute exercise in the presence of hyperglycemia (T2D) and obesity. The overall goal of my project is to characterize reversible phosphorylation of mitochondrial proteins in human skeletal muscles in response to insulin and acute exercise, and how potential abnormalities in the phosphorylation of mitochondrial proteins in response to these stimuli in obesity and T2D relate to defects in insulin-stimulated glucose metabolism and insulin signaling. 16 The Molecular Endocrinology Unit (KMEB) expression of telomerase gene (hTERT) in hMSC leads to rescuing the senescent phenotype of hMSC and also enhanced their differentiation capacity. The biological function of telomerase activity regarding mMSC diff & bone formation is not known. Therefore, the aim of this project is to understand the physiological role of telomerase in osteogenic stem cell proliferation and differentiation and also its effects on bone homeostasis in vivo by using TERC knockout mouse model that lacks telomerase activity due to null mutation in RNA component (TERC). Lasse Kjær, MSc The potential for the generation of nerve cells from human embryonic stem cells Human embryonic stem cells (hESCs) have the ability for unlimited self-renewal and the potential for generating all cell types of the human adult body. By these virtues they present a prospective source of cells for treatment of diseases resulting from cellular, such as Parkinson’s disease. In this thesis it was shown that the hESC lines OD3 and HUES9 had a normal karyotype and were maintained in the undifferentiated state. Differentiation of the cell lines revealed that OD3 had a predisposition for generation of the mesodermal germlayer, and HUES9 for the ectodermal germlayer. Inhibition of the TGF-b/Activin/ Nodal and BMP signalling pathways during differentiation was found to promote generation of neuroectoderm. It was furthermore found that exogenous Retinoic acid resulted in a concentration dependent acquisition of neural rostrocaudal identity and was found to increase the number of tyrosine hydroxylase positive neurons for certain concentrations of RA. Maria E. O. Nielsen, MSc Identification and characterization of membrane marker proteins selective for adipogenesis, chondrogenesis, and osteogenesis in human mesenchymal stem cells using quantitative proteomics and live-cell imaging in combination with RNA interference We have identified and quantified proteins from plasma membrane selective for adipogenesis and osteogenesis using a high-through put proteomics strategy. By comparing the protein profiles for each differentiation pathway it is possible to distinguish which proteins are selectively up- or down-regulated in each of the two differentiation processes. These proteins will be validated with fluorescence microscopy among others methods. Ann Dorte Storm Pørneki, MSc Derivation of pancreatic progenitor cells from human embryonic stem cells Kenneth Hauberg Larsen, MSc Differentiation of human embryonic stem cells into osteogenic precursor cells through mesodermal induction A transplantable source of β-cells for the treatment of Diabetes type I could be obtained from the directed in vitro differentiation of human embryonic stem cells (hESC). To achieve the goal of functional cells for therapy it is necessary to recapitulate the embryonic development and to direct the hESC through the various developmental stages along the path to mature β-cells. The first step in this directed in vitro differentiation is the induction of definitive endoderm. This is accomplished by a combination of high TGF-β/Activin A signalling and low PI3Ksignalling. The aim is to differentiate these endodermal progenitor cells further towards cells with markers of foregut and ultimately to pancreas progenitor cells. Human mesenchymal stem cells or bone marrow derived marrow stromal cells (hMSC) represents a group of stem cells located in the bone marrow stroma. They are capable of multilineage differentiation into various mesodermlike cells such as adipocytes, chondrocytes, myoblasts and osteoblasts. MSCs are important candidates to be employed in cell-based therapy for a variety of diseases ranging from osteogenesis imperfecta, bone and cartilage defects, and achilles tendon repair. The focus of our group is to understand the cellular and molecular mechanisms controlling bone formation. This is relevant since one major disease affecting the elderly population: osteoporosis is the result of age-related bone loss due to decreased bone formation. Recently, our group has employed large scale screening strategies of geneomics and proteomics in order to identify factors controlling bone formation as well as novel markers associated with osteoblastic phenotype in vitro. The aim of this study is to functionally verify novel markers identified by SILAC-based proteomics and to study their possible regulatory role during osteoblast differentiation, as well as their possible use for isolating specific cell populations of hMSC with bone forming phenotype. We will employ a variety of methods to verify Hamid Saeed, Msc The Physiological role of telomerase enzyme in osteoblast differentiation in vitro and bone homeostasis in vivo Osteoporosis is a multifactorial and multifaceted disorder leading to an increased risk for osteoporotic fractures. Senescent micro-environment due to aging coupled with telomerase deficiency resulted in accumulation of senescent osteogenic stem cells that imprecise the differentiation of mesenchymal stem cells. It is well documented that telomerase activity is one of the limiting factors that accelerated cellular senescence and decreased organ regeneration. We have demonstrated that ectopic over- 17 these results and to identify important and relevant markers. Cell sorting of specific populations that are positive for potential markers will be examined for their in vitro and in vivo differentiation. In order to identify a possible role of these markers in osteoblast differentiation, we will block or over express these proteins, and study the effects on osteoblast differentiation. Furthermore we aim to functionally test the osteogenic potential of prospectively isolated hMSC in vivo employing novel 3D-osteoconductive scaffolds. Traditionally, we have employed hydroxyapatite/tricalcium phosphate (HA/TCP). Recently and through collaboration with several biotech companies, University of Aarhus, and the iNANO center, we have access to a variety of novel scaffolds. We will test the ability of these scaffolds to enhance bone formation of the prospectively isolated cell and to compare the efficiency of bone formation with that observed in HA/TCP using histomorphometric methods developed in our lab. have recently confirmed that this mechanism also seem to occur in HBM patients from Fyn. To further investigate the mechanism behind HBM caused by mutation in Lrp5, we are studying the effects of serum obtained from these patients on mesenchymal stem cells (MSC). These results show that serum from HBM patients promote the differentiation of MSC into osteoblasts while inhibiting differentiation into adipocytes. These differences seem not to depend on serotonin and we are studying what alternative components of serum causes these effects. Abbas Jafari Kermani, MSc Identification of kinases that determine differentiation of Human Mesenchymal Stem Cells into osteoblastic cells and their use as therapeutic targets for modifying osteoblast differentiation and enhancing bone formation Human Mesenchymal Stem Cells have the potential to be differentiated into a variety of cell types including osteoblasts and they are considered as a very attractive cell type to be used in cell therapy of bone related diseases. Looking into the mechanisms which govern osteogenic differentiation of MSCs is of great importance, as this can lead to development of new drugs, as well as, strategies to improve bone forming ability of these cells. Therefore, the aim of this project is to identify kinases which control osteoblastic differentiation of hMSCs, using a high-throughput siRNA library screening, using a library which contains 3 different siRNAs for each of the ~800 known kinases represented in the human genome. In order to assess the effect of each kinase knock down on the osteoblastic differentiation of hMSCs, Alkaline phosphatase activity will be quantified. Having identified kinases that positively or negatively influence osteoblastic differentiation, we will perform verification experiments, both in vitro and in vivo. Tom E. Andersen, MSc Regulation of bone mass by Lrp5 and the influence of Lrp5-T253I in bone remodelling Bone is a dynamic tissue that undergoes a balanced process of bone formation (mediated by bone forming cells; osteoblasts) and bone resorption (mediated by bone resorbing cells; osteoclasts). This bone remodelling occurs throughout life and constantly adjusts the strength of the bones to conform to the physical stress of weight load on the bones. Disturbance of this process gives rise to diseases in the skeletal system with either increased (high bone mass, HMB) or decreased bone mass (osteoporosis). As the life expectancy of the population in the modern world is constantly increasing and because osteoporosis is a common disease especially in elderly people, the number of people suffering from osteoporosis is expected to increase in the future. At present, treatment of osteoporosis primarily targets bone resorption by inhibiting the osteoclasts. Often however the primary cause of osteporosis is not due to high bone resorption by osteoclasts but due to too low bone formation by osteoblasts. To date only a single treatment (PTH approved by FDA, 2006) targets osteoblasts in order to increase bone formation. It is therefore much needed to reach a better understanding of how mature osteoblasts regulate the bone mass and how to increase their bone forming ability. The Pituitary – and Clinical Nutrition Research Group Kristian Wraae, MD Odense Androgen and Growth Factor Study in Elderly Men The project is a clinical investigation of 800 men between 60 and 75 years of age. Primarily, we investigated the relationship between androgens, growth factors and other hormones, on one hand, and body composition (muscle, fat and bone) and physical ability (strength and physical performance) on the other hand. Moreover, we investigate the importance of various genes and lifestyle factors for the correlation between hormones and body composition/physical ability. In addition, the study will answer questions regarding aging and the causes of decreasing androgen levels and growth factor levels in the blood. The LRP5 protein belongs to the low density lipoprotein receptor (LDLR) family, which are cell surface proteins that bind and internalize ligands. LRP5 function as a coreceptor of wnt factors and recently it was shown also to regulate the level of serotonin in blood from the gut. People having an inactivating mutation in Lrp5 suffer from severe osteoporosis while people having an activating mutation have HBM. This occurs by an effect of these mutations on the circulating levels of serotonin in blood which affects proliferation of osteoblasts in bone. We 18 Louise Frederiksen, MD Odense Androgen Study - The effect of Testim and training in a population based, randomized, placebo controlled, double blinded study on hypogonadal men Søren Fast, MD, PhD student The effect of pretreatment with 0.1 mg of recombinant human TSH (rhTSH) on thyroid 131I uptake and goitre volume reduction, following 131I-therapy for non-toxic benign nodular goitre. A randomized double blinded, placebo-controlled trial Testosterone is widely used to treat relative hypogonadism in elderly males, but the indication for treatment and safety of treatment is still being debated. This study will examine the effect of testosterone (gel) on body composition, insulin sensitivity, physical performance, muscle strength, sexual function and quality of life. The study duration is 6 months. 60 males (60-78 years) are randomized into groups (testosterone, placebo and strength training) and the strength training group is further randomized to placebo or testosterone after 3 months. Examination program, including physical testing, MRI spectroscopy, DXA and euglyceamic clamp will be conducted every three months. The main objective of this study is to examine whether the amplification of 131I-therapy with 0.1 mg of rhTSH allows a 131I-dose reduction, from 100 Gy to 50 Gy, in non-toxic nodular goitre patients. In addition the optimal time interval between rhTSH administration and 131Itherapy is studied. The Clinical Nursing Research Group Mette Rothmann, cand.scient.san Risk stratified screening for osteoporosis in Region Syddanmark – a study focusing on the patient perspective. The Thyroid Research Group The purpose is to focus on the significance, the procedure and the experience obtained by participating in a screening process. As part of this study women’s own assessments of risk of bone fractures as well as other factors of influence will be evaluated. The hypothesis is that the patient perspective is important if current screening programmes are to be implemented successfully, and this study will provide knowledge both to be used for targeted information about a screening programme as well as communication of and follow-up on the screening result. Daniel El-Fassi, MD, PhD student Clinical and immunological aspects of B-lymphocyte depletion in Graveś disease We have conducted a controlled, clinical study evaluating the effect of B lymphocyte depletion with rituximab on autoantibody levels, autoantibody specificity, thyroid function, and ophthalmic findings in Graves’ disease. Further studies adressing changes in the immune functions of the patients are ongoing. Thyroid examination 19 RESEARCHERS AND TECHNICAL/ADMINISTRATIVE STAFF IN EFE AS PER 31 DECEMBER 2009 Anne Holm Nyland, MSc in nursing, RN (clinical development nurse, Department of Endocrinology, Odense University Hospital) Lillian Petersen (nurse, Department of Endocrinology, Odense University Hospital) Lene Borgen Esman, (nurse, Department of Endocrinology, Odense Univesity Hospital) Carina Rebsdorf, (nurse, Department of Endocrinology, Odense Univesity Hospital) The Bone and Calcium Research Group Researchers Kim Torsten Brixen, Associate Professor, PhD (consultant, Department of Endocrinology, Odense University Hospital) Pernille Hermann, PhD (consultant, Department of Endocrinology, Odense University Hospital) PhD students PhD student Dorthe Nielsen, RN (MHS, PhD-student. University of Southern Denmark) Morten Frost Nielsen, MD (Department of Endocrinology, Odense University Hospital) Katrine Hass Rubin, Pt, MHS, (Department of Endocrinology, Odense University Hospital) Stinus Hansen, MD (Department of Endocrinology, Odense University Hospital) Mette Rothmann (nurse, Department of Endocrinology, Odense University Hospital) The Diabetes Research Group Researchers Henning Beck-Nielsen, Professor, DMSc, head of research (consultant, Department of Endocrinology, Odense University Hospital) Michael Gaster, MD, PhD (Assistant Research Professor, KMEB, Department of Endocrinology, Odense University Hospital) Jan Erik Henriksen, MD, PhD (consultant, Department of Endocrinology, Odense University Hospital) Ole Hother-Nielsen, DMSc (consultant, Department of Endocrinology, Odense University Hospital) Kurt Højlund, MD, PhD (Senior House Officer, Department of Endocrinology, Odense University Hospital) Dorte Møller Jensen, PhD (Senior House Officer, Department of Endocrinology, Odense University Hospital) Tine Thingholm, MSc, PhD (Department of Endocrinology, Odense University Hospital) Knud Yderstræde, PhD (consultant, Department of Endocrinology, Odense University Hospital) Torben Hansen, MD, PhD (adj. Professor, Department of Endocrinology, Odense University Hospital, University of Southern Denmark and Steno Diabetes Center) Aase Handberg, DMSc, PhD (Ass. professor, Department of Endocrinology, Odense University Hospital and Unviersity of Southern Denmark) External researchers Signe Beck-Nielsen, MD (House Officer, Afd. H, OUH + Esbjerg Centralsygehus) Ellen Hamborg-Petersen, MD (House Officer, Esbjerg Centralsygehus) Claus Lohman Brasen, MD (Department of Biochemistry, Pharmacology and Genetics, Odense University Hospital) Lars Folkestad, MD, (Esbjerg Central Hospital) Mikkel Høiberg, MD, Kristiansand, Norge Technical/administrative staff Donna Arbuckle-Lund (technologist), Elsebeth Byrge (secretary), Sandra Harris Nielsen (secretary), Anette R. Madsen (technologist), Steffanie Anthony Christensen (technologist), Elizabeth Hanmann (technologist), Lotte Hørlyck (technologist), Jeanette Lindegaard (technologist), Jane Nielsen (technologist), Jane Nielsen (technologist), Mette Brøchner Hansen (technologist). Clinical Nursing Research Group PhD students Charlotte Mose (head nurse, Department of Endocrinology, Odense University Hospital Lone Hammelsvang (nurse, Department of Endocrinology, Odense University Hospital) Helle Vagner Nielsen (nurse, Department of Endocrinology, Odense University Hospital) Lisbeth Minet, PT, MHS, Ph.D.-student (Department of Endocrinology, Odense University Hospital) Birgitte Vind, MD (Department of Endocrinology, Odense University Hospital) Christina Anne Vinter, MD, (Department of Gynaecology, Odense University Hospital) 20 PhD students Xiaolu Zhao, MSc, (Institute of Biochemistry and Molecular Biology, University of Southern Denmark) Lena Sønder Snogdal, MD (Department of Endocrinology, Odense University Hospital) Steffen Bak, MSc (Dept. of Biochemistry and Molecular Biology, University of Southern Denmark) Ann Dorte Pørneki, MSc (KMEB, Department of Endocrinology, Odense University Hospital) Hamid Saeed, Msc, (KMEB, Department of Endocrinology, Odense University Hospital) Tom E. Andersen, MSc (KMEB, Department of Endocrinology, Odense University Hospital) Maria E. O. Nielsen, Msc (CEBI, University of Southern Denmark & KMEB, Department of Endocrinology, Odense University Hospital) Abbas Jafari Kermani, MSc (Institute of Medical Biology, University of Southern Denmark) Diyako Qânie, MSc (KMEB, Department of Endocrinology, Odense University Hospital) External researchers Klaus Brusgaard, MSc, PhD (molecular biologist, Department of Clinical Biochemistry, Genetics and Pharmacology, Odense University Hospital) Klaus Levin, MD, PhD (staff specialist, Svendborg Hospital) Pernille Poulsen, PhD (post.doc., Steno Diabetes Center, Gentofte) Henrik Støvring, MSc (Institute of Public Health, General Practice Research Unit, University of Southern Denmark) Jørgen Wojtaszenski, PhD, (Institute of August Krogh, University of Copenhagen) Other students Pernille Rasmussen, Thesis student Mohamed Abdelgawad, Research Trainee Olena Kucheryavenko, Research Trainee Technical/administrative staff Nanett Mosumgaard (research secretary), Charlotte Olsen (technologist), Lone Hansen (technologist), Vibe Vestergaard (research nurse), Ewa Romancsuk ( research nurse), Kristine Michailidis (research secretary), Irene Lynfort (technologist), Jeanett Agergaard (technologist), Ariane Minet (MSc) Technical/administrative staff Tina Hansen Barbisan (research secretary), Tina K.L. Nielsen (technologist), Bianca Jørgensen (technologist), Stephanie Shouse (technologist), Helle Hansen (assistant), Lone Christiansen (technologist) The Molecular Endocrinology Unit (KMEB) Researchers Moustapha Kassem, Professor, DMSc, PhD (consultant, KMEB, Department of Endocrinology, Odense University Hospital) Basem Abdallah, MSc, PhD, Lecturer (KMEB, Department of Endocrinology, Odense University Hospital) Jorge Burns, MSc, PhD, Assistant Research Professor (KMEB, Department of Endocrinology, Odense University Hospital) Nicholas Ditzel, Research Assistant (KMEB, Department of Endocrinology, Odense University Hospital ) Linda Harkness, MPhil, Research Assistant (KMEB, Department of Endocrinology, Odense University Hospital) Weimin Qiu, Assistant Research Professor (KMEB, Department of Endocrinology, Odense University Hospital) Kenneth Hauberg, Research assistant (KMEB, Department of Endocrinology, Odense University Hospital) Li Chen, Assistant research professor (KMEB, Department of Endocrinology, Odense University Hospital) Amer Mahmood, Research assistant (KMEB, Department of Endocrinology, Odense University Hospital) Lars Peter Kristensen, Research assistant (KMEB, Department of Endocrinology, Odense University Hospital) 21 The Pituitary- and Clinical Nutrition Research Group The Thyroid Research Group Researchers Laszlo Hegedüs, DMSc (Professor, consultant, Department of Endocrinology, Odense University Hospital) Steen Joop Bonnema, MD, PhD (Consultant, Department of Endocrinology, Odense University Hospital) Thomas Heiberg Brix, MD, PhD (Senior House Officer, Department of Endocrinology, Odense University Hospital) Pia Skov Hansen, MD, PhD (Post.doc., Department of Endocrinology, Odense University Hospital, and Institute of Public Health, Epidemiology, University of Southern Denmark) Helle Døssing, MD, PhD (consultant, Department of Oto-rhino-laryngology, Odense University Hospital) Viveque Egsgaard Nielsen, MD, PhD (Department of Oto-rhino-laryngology, Århus University Hospital) Anina L. Jensen, BSc (Department of Endocrinology, Odense University Hospital) Frans B. Kristensen, MD (Senior Registrar, Department of Endocrinology, Odense University Hospital) Researchers Marianne Andersen, PhD (consultant, Department of Endocrinology, Odense University Hospital) Rene Klinkby Støving, PhD (consultant, Department of Endocrinology, Odense University Hospital) Dorte Glintborg, MD, PhD (Medical Department, Kolding Hospital) Torben Leo Nielsen (House Officer, Medical Department, Odense University Hospital) Magdalena Andries, MD (House Officer, Medical Department, Odense University Hospital) Laima Saudaskiene (House Officer, Medical Department, Odense University Hospital) Alin Andries, MD (Department of Endocrinology, Odense University Hospital) Laura Vad Winkler, MD (Medical Department, Svendborg Hospital) Ida Ringsborg Madsen, MD (Department of Endocrinology, Odense Univesity Hospital) Stina Bolette Martin, MD (Department of Endocrinology, Odense Univesity Hospital) Linnéa E. Lingqvist, MD (Department of Endocrinology, Odense University Hospital) PhD students Daniel El-Fassi, MD (Department of Endocrinology, Odense University Hospital) Søren Fast, MD (Department of Endocrinology, Odense University Hospital) PhD students Kristian Wraae, MD (Department of Endocrinology, Odense University Hospital) Louise Frederiksen, MD (Department of Endocrinology, Odense University Hospital) Hanne Mumm, MD (Department of Endocrinology, Odense University Hospital External researchers Finn N. Bennedbæk, MD, PhD (Consultant, Department of Endocrinology, Herlev Hospital, University of Copenhagen) Malene Boas, MD (clinical assistant, PhD student House Officer, Department of Growth and Reproduction, Rigshospitalet, University of Copenhagen) Esther Jensen, MD (consultant, Department of Clinical Biochemistry, Hillerød Hospital) Claus H. Nielsen, MD, MSc, PhD (Consultant, Institute of Inflammation Research, Rigshospitalet, University of Copenhagen) Torquil Watt, MD (PhD student, Endocrine Clinic, Abdominal Center, Rigshospitalet) Terry J. Smith, MSD, PhD (Department of Ophtamology an Visual Sciences, Kellogg Eye Center and Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, USA) Birte Kristensen, MSc (Clinical Assistant, Institute of Inflammation Research, Rigshospitalet, Copenhagen, and Department of Endocrinology, Odense University Hospital) External researchers Thue Kvorning, MSc (Institute of Sport Sciences and Biomechanics, University of Southern Denmark) Klavs Madsen (Institute of Sport Sciences and Biomechanics, University of Southern Denmark) Claus Hagen, DMSc (consultant, Department of Endocrinology, Gentofte Hospital) Jan Frystyk, PhD (consultant, Medical Research Laboratories, Aarhus University Hospital) Allan Flyvbjerg (Professor, consultant, Medical Research Laboratories, Clinical Institute, Aarhus University Hospital) Joanna Ganc-Petersen (Senior House Officer, Department of Orthopaedic Surgery, Fredericia Hospital) Kirsten Hørder, MD (consultant, Center for Eating Disorders, Odense University Hospital) Niels Bilenberg, MD (professor, Department of Child Psychiatry, Odense University Hospital) Per Nøhr-Jensen, MD (consultant, Center for Eating Disorders, Odense University Hospital) Technical/administrative staff Ellen Andersen (technologist), Henny Hansen (technologist), Annagrethe Jeppesen (technologist), Susanne Møller (technologist), Berit Knold (dietician), Mette Hansen (clinical assistant). 22 COMPLETED PHD THESES Jesper Ryg The Frail Hip. A study on the risk of second hip fracture, prevalence of osteoporosis and adherence to treatment in patients with recent hip fracture. Malthe Kristiansen Isolation and characterisation of human mesenchymal stem cells from bone marrow and their potential use in therapy. Iben Brock Jacobsen New Aspects of insulin treatment in type 1 diabetes. Amer Mahmood Differentiation of human embryonic stem cells into osteogenic precursor cells through mesodermal induction. Martin Mogensen Mitochondrial function in patients with type 2 diabetes. Lars Peter Kristensen Using quantitative proteomics methods for studying the secreteome of human mesenchymal stem cells during osteoblast differentiation. Mikael Kjær Poulsen Prevalence of macrovascular disease in Type 2 Diabetes Mellitus: Left ventricular diastolic dysfunction, myocardial ischemia and peripheral vascular insufficiency. Stem cell research 23 PUBLICATIONS (peer reviewed papers and book chapters) 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. Abdallah, Basem ; Kassem, Moustapha. I: Journal of Cellular Physiology. 2009 ; vol. 218, nr. 1, Jan. United States. s. 9-12 /The use of mesenchymal (skeletal) stem cells for treatment of degenerative diseases: current status and future perspectives. Abrahamsen, B ; Eiken, P ; Brixen, K. I: Journal of Internal Medicine. 2009 ; vol. 265, nr. 5, 2009-May. England. s. 581-92 / Atrial fibrillation in fracture patients treated with oral bisphosphonates. Bay-Jensen, Anne-Christine ; Tabassi, Nadine ; Sondergaard, Lene ; Andersen, Thomas ; Dagnaes-Hansen, Frederik ; Garnero, Patrick ; Kassem, Moustapha ; Delaisse, Jean-Marie. I: Arthritis Research & Therapy. 2009 ; vol. 11, nr. 1, 2009-Jan-20. s. R9 / The response to estrogen deprivation on cartilage collagen degradation markers; CTX-II is unique compared to other markers of collagen turnover. Beck-Nielsen, Signe ; Jacobsen, Bendt ; Gram, Jeppe ; Brixen, Kim ; Jensen, Tina Kold. I: European Journal of Endocrinology. 2009 ; vol. 160, nr. 3, s. 491-497 / Incidence and prevalence of nutritional and hereditary rickets in southern Denmark. Beck-Nielsen, Signe ; Jensen, Tina Kold ; Gram, Jeppe ; Brixen, Kim ; Brock-Jacobsen, Bendt. I: European Journal of Pediatrics. 2009 ; vol. 168, nr. 8, August. s. 941-949 / Nutritional rickets in Denmark : a retrospective review of children’s medical records from 1985 to 2005. Bellantuono, Ilaria ; Aldahmash, Abdullah ; Kassem, Moustapha. I: Biochimica et Biophysica Acta. 2009 ; vol. 1792, nr. 4, 2009-Apr. Netherlands. s. 364-70 / Aging of marrow stromal (skeletal) stem cells and their contribution to age-related bone loss. Boas, Malene ; Hegedüs, Laszlo ; Feldt-Rasmussen, Ulla ; Skakkebaek, Niels E ; Hilsted, Linda ; Main, Katharina M. I: Journal of Clinical Endocrinology and Metabolism. 2009 ; vol. 94, nr. 10, 2009-Oct. United States. s. 4031-5 / Association of thyroid gland volume, serum insulin-like growth factor-I, and anthropometric variables in euthyroid prepubertal children. Boesgaard, Trine Welløv ; Gjesing, Anette Prior ; Grarup, Niels ; Rutanen, Jarno ; Jansson, Per-Anders ; Hribal, Marta Letizia ; Sesti, Giorgio ; Fritsche, Andreas ; Stefan, Norbert ; Staiger, Harald ; Häring, Hans ; Smith, Ulf ; Laakso, Markku ; Pedersen, Oluf ; Hansen, Torben ; EUGENE2 Consortium. I: PLoS ONE. 2009 ; vol. 4, nr. 9, 2009-null. United States. s. e7236 / Variant near ADAMTS9 known to associate with type 2 diabetes is related to insulin resistance in offspring of type 2 diabetes patients - EUGENE2 study. Bonnema, Steen J ; Hegedüs, Laszlo. I: Current opinion in endocrinology, diabetes, and obesity. 2009 ; vol. 16, nr. 5, 2009-Oct. England. s. 379-84 / A 30-year perspective on radioiodine therapy of benign nontoxic multinodular goiter. Bouatia-Naji, Nabila ; Bonnefond, Amélie ; Cavalcanti-Proença, Christine ; Sparsø, Thomas ; Holmkvist, Johan ; Marchand, Marion ; Delplanque, Jérôme ; Lobbens, Stéphane ; Rocheleau, Ghislain ; Durand, Emmanuelle ; De Graeve, Franck ; Chèvre, JeanClaude ; Borch-Johnsen, Knut ; Hartikainen, Anna-Liisa ; Ruoko- 24 11. 12. 13. 14. 15. 16. 17. 18. nen, Aimo ; Tichet, Jean ; Marre, Michel ; Weill, Jacques ; Heude, Barbara ; Tauber, Maithé ; Lemaire, Katleen ; Schuit, Frans ; Elliott, Paul ; Jørgensen, Torben ; Charpentier, Guillaume ; Hadjadj, Samy ; Cauchi, Stéphane ; Vaxillaire, Martine ; Sladek, Robert ; Visvikis-Siest, Sophie ; Balkau, Beverley ; Lévy-Marchal, Claire ; Pattou, François ; Meyre, David ; Blakemore, Alexandra I F ; Jarvelin, Marjo-Riita ; Walley, Andrew J ; Hansen, Torben ; Dina, Christian ; Pedersen, Oluf ; Froguel, Philippe. I: Nature Genetics. 2009 ; vol. 41, nr. 1, 2009-Jan. United States. s. 89-94 / A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Boström, Pontus ; Andersson, Linda ; Li, Lu ; Perkins, Rosie ; Højlund, Kurt ; Borén, Jan ; Olofsson, Sven-Olof. I: Biochemical Society Transactions. 2009 ; vol. 37, nr. Pt 5, Oct. England. s. 981-5 / The assembly of lipid droplets and its relation to cellular insulin sensitivity. Brand, Oliver J ; Barrett, Jeffrey C ; Simmonds, Matthew J ; Newby, Paul R ; McCabe, Christopher J ; Bruce, Christopher K ; Kysela, Boris ; Carr-Smith, Jackie D ; Brix, Thomas ; Hunt, Penny J ; Wiersinga, Wilmar M ; Hegedüs, Laszlo ; Connell, John ; Wass, John A H ; Franklyn, Jayne A ; Weetman, Anthony P ; Heward, Joanne M ; Gough, Stephen C L. I: Human Molecular Genetics. 2009 ; vol. 18, nr. 9, 2009-May-1. England. s. 1704-13 / Association of the thyroid stimulating hormone receptor gene (TSHR) with Graves’ disease. Brix, Thomas Heiberg ; Hansen, Pia Skov ; Kyvik, Kirsten Ohm ; Hegedüs, Laszlo. I: Journal of Clinical Endocrinology and Metabolism. 2009 ; vol. 94, nr. 11, 2009-Nov. United States. s. 4439-43 / Aggregation of thyroid autoantibodies in twins from opposite-sex pairs suggests that microchimerism may play a role in the early stages of thyroid autoimmunity. Brix, Thomas Heiberg ; Hansen, Pia Skov ; Bennedbak, Finn Noe ; Bonnema, Steen Joop ; Kyvik, Kirsten Ohm ; Ørstavik, Karen Helene ; Hegedüs, Laszlo. I: Twin Research and Human Genetics. 2009 ; vol. 12, nr. 5, 2009-Oct. Australia. s. 502-6 / X Chromosome inactivation pattern is not associated with interindividual variations in thyroid volume: a study of euthyroid danish female twins. Brixen, Kim ; Kroustrup, Jens Peter. I: Medicinsk kompendium. / red. Ove B Schaffalitzky de Muckadell ; Stig Haunsø ; Hendrik Vildstrup. Bd. 2 17. udg. Nyt Nordisk Forlag / Schønberg Forlag / Arnold Busck, 2009. s. 2389-2392 / Multiple endokrine neoplasier. Brixen, Kim. I: Praktisk medicin. / red. Hansen Jens Georg. Dagens medicin Bøger, 2009. s. 207-263 / Endokrine sygdomme. Charni-Ben Tabassi, N ; Richardot, P ; Toh, L ; Marotte, H ; Jensen, Anne-Christine Bay ; Miossec, P ; Garnero, P. I: Annals of the Rheumatic Diseases. 2009 ; vol. 68, nr. 3, 2009-Mar. England. s. 451-2 / Circulating nitrated N-telopeptide of type III collagen (IIINys) as a biochemical marker of oxidative-related synovial tissue metabolism in rheumatoid arthritis. Chen, Muwan ; Feng, Wenzhou ; Cao, Hui ; Zou, Lijin ; Chen, Chungui ; Baatrup, Anette ; Nielsen, Anne Bay ; Li, Haisheng ; Kassem, Moustapha ; Zou, Xuenong ; Bünger, Cody. I: Journal of 19. 20. 21. 22. 23. 24. 25. 26. ethnopharmacology. 2009 ; vol. 125, nr. 1, 2009-Aug-17. Ireland. s. 75-82 / A traditional Chinese medicine formula extracts stimulate proliferation and inhibit mineralization of human mesenchymal stem cells in vitro. Christensen, Signe Engkjær ; Nissen, Peter H ; Vestergaard, Peter ; Heickendorff, Lene ; Rejnmark, Lars ; Brixen, Kim ; Mosekilde, Leif. I: Clinical Endocrinology. 2009 ; vol. 71, 2009-Feb-25. s. 798807 / Skeletal consequences of familial hypocalciuric hypercalcaemia versus primary hyperparathyroidism. Clausen, Tine D ; Mathiesen, Elisabeth R ; Hansen, Torben ; Pedersen, Oluf ; Jensen, Dorte M ; Lauenborg, Jeannet ; Schmidt, Lone ; Damm, Peter. I: Journal of Clinical Endocrinology and Metabolism. 2009 ; vol. 94, nr. 7, 2009-Jul. United States. s. 2464-70 / Overweight and the metabolic syndrome in adult offspring of women with diet-treated gestational diabetes mellitus or type 1 diabetes. Dahl, Sandra Rinne ; Kleiveland, Charlotte Ramstad ; Kassem, Moustapha ; Lea, Tor ; Lundanes, Elsa ; Greibrokk, Tyge. I: Journal of chromatography. A. 2009 ; vol. 1216, nr. 22, 2009-May-29. Netherlands. s. 4648-54 / Determination of thromboxanes, leukotrienes and lipoxins using high-temperature capillary liquid chromatography-tandem mass spectrometry and on-line sample preparation. Douglas, Raymond S ; Tsirbas, Angelo ; Gordon, Mark ; Lee, Diana ; Khadavi, Nicole ; Garneau, Helene Chokron ; Goldberg, Robert A ; Cahill, Kenneth ; Dolman, Peter J ; Elner, Victor ; Feldon, Steve ; Lucarelli, Mark ; Uddin, Jimmy ; Kazim, Michael ; Smith, Terry J ; Khanna, Dinesh ; Hegedüs, Laszlo ; International Thyroid Eye Disease Society. I: Archives of Ophthalmology. 2009 ; vol. 127, nr. 9, 2009-Sep. United States. s. 1155-60 / Development of criteria for evaluating clinical response in thyroid eye disease using a modified Delphi technique. Douglas, Raymond S ; Brix, Thomas H ; Hwang, Catherine J ; Hegedüs, Laszlo ; Smith, Terry J. I: Journal of Clinical Endocrinology and Metabolism. 2009 ; vol. 94, nr. 5, 2009-May. United States. s. 1797-802 / Divergent frequencies of IGF-I receptor-expressing blood lymphocytes in monozygotic twin pairs discordant for Graves’ disease: evidence for a phenotypic signature ascribable to nongenetic factors. Eastell, Richard ; Nickelsen, Thomas ; Marin, Fernando ; Barker, Clare ; Hadji, Peyman ; Farrerons, Jordi ; Audran, Maurice ; Boonen, Steven ; Brixen, Kim ; Melo Gomes, Jose ; Obermayer-Pietsch, Barbara ; Avramidis, Avraam ; Sigurdsson, Gunnar ; Glüer, Claus C. I: Journal of Bone and Mineral Research. 2009 ; vol. 24, nr. 4, Apr. s. 726-36 / Sequential Treatment of Severe Postmenopausal Osteoporosis Following Teriparatide: Final Results of the Randomized, Controlled European Study of Forsteo (EUROFORS): Trial registration: clinicaltrials.gov identifier NCT00191425 (Trial regi stration date: 12 September 2005). Fast, Søren ; Nielsen, Viveque Egsgaard ; Grupe, Peter ; Bonnema, Steen Joop ; Hegedüs, Laszlo. I: Journal of Nuclear Medicine. 2009 ; vol. 50, nr. 5, 2009-May. United States. s. 732-7 / Optimizing 131I Uptake After rhTSH Stimulation in Patients with Nontoxic Multinodular Goiter : Evidence from a Prospective, Randomized, DoubleBlind Study. Fast, Søren ; Nielsen, Viveque ; Bonnema, Steen ; Hegedus, Laszlo. I: European Journal of Endocrinology. 2009 ; vol. 160, nr. 4, s. 517528 / Time to reconsider nonsurgical therapy of benign nontoxic 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 25 multinodular goitre. Focus on recombinant human TSH (rhTSH) augmented radioiodine therapy. Fast, Søren ; Nielsen, Viveque Egsgaard ; Grupe, Peter ; Bonnema, Steen Joop ; Hegedüs, Laszlo. I: Journal of Nuclear Medicine. 2009 ; vol. 50, nr. 5, 2009-May. United States. s. 732-7 / Optimizing 131I Uptake After rhTSH Stimulation in Patients with Nontoxic Multinodular Goiter : Evidence from a Prospective, Randomized, DoubleBlind Study. Faerch, Kristine ; Vaag, Allan ; Holst, Jens J ; Hansen, Torben ; Jørgensen, Torben ; Borch-Johnsen, Knut. I: Diabetes Care. 2009 ; vol. 32, nr. 3, 2009-Mar. United States. s. 439-44 / Natural history of insulin sensitivity and insulin secretion in the progression from normal glucose tolerance to impaired fasting glycemia and impaired glucose tolerance: the Inter99 study. Finucane, F ; Luan, J ; Wareham, N ; Sharp, S ; O’Rahilly, S ; Balkau, B ; Flyvbjerg, A ; Walker, M ; Højlund, K ; Nolan, J ; (on behalf of the European Group for the Study of Insulin Resistance: Relationship between Insulin Sensitivity and Cardiovascular Disease Risk Study Group) ; Savage, D. I: Diabetologia. 2009 ; vol. 52, nr. 11, 2009-Sep-12. s. 2345-2349 / Correlation of the leptin : adiponectin ratio with measures of insulin resistance in non-diabetic individuals. Frederiksen, L ; Nielsen, T L ; Wraae, K ; Hagen, C ; Frystyk, J ; Flyvbjerg, A ; Brixen, K ; Andersen, M. I: Journal of Clinical Endocrinology and Metabolism. 2009 ; vol. 94, nr. 10, 2009-Oct. United States. s. 4010-5 / Subcutaneous rather than visceral adipose tissue is associated with adiponectin levels and insulin resistance in young men Gastaldelli, Amalia ; Kozakova, Michaela ; Højlund, Kurt ; Flyvbjerg, Allan ; Favuzzi, Angela ; Mitrakou, Asimina ; Balkau, Beverley ; RISC Investigators. I: Hepatology. 2009 ; vol. 49, nr. 5, 2009May. United States. s. 1537-44 / Fatty liver is associated with insuqlin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population Gaster, Michael. I: Biochemical and Biophysical Research Communications. 2009 ; vol. 382, nr. 4, 2009-May-15. United States. s. 766-70 / Reduced lipid oxidation in myotubes established from obese and type 2 diabetic subjects. Gaster, Michael. I: Biochemical and Biophysical Research Communications. 2009 ; vol. 387, nr. 4, 2009-Oct-2. United States. s. 651-5 / Reduced TCA flux in diabetic myotubes: A governing influence on the diabetic phenotype? Gjerstorff, Morten ; Burns, Jorge S ; Nielsen, Ole ; Kassem, Moustapha ; Ditzel, Henrik. I: American Journal of Pathology. 2009 ; vol. 175, nr. 1, 2009-Jul. United States. s. 314-23 / Epigenetic moqdulation of cancer-germline antigen gene expression in tumorigenic human mesenchymal stem cells: implications for cancer therapy. Gjesing, Anette P ; Sparsø, Thomas ; Borch-Johnsen, Knut ; Jørgensen, Torben ; Pedersen, Oluf ; Hansen, Torben ; Olsen, Niels V. I: PLoS ONE. 2009 ; vol. 4, nr. 9, 2009-null. United States. s. e7206 / No consistent effect of ADRB2 haplotypes on obesity, hypertension and quantitative traits of body fatness and blood pressure among 6,514 adult danes. Glintborg, Dorte ; Andersen, Marianne ; Richelsen, Bjørn ; Bruun, Jens M. I: Clinical Endocrinology. 2009 ; vol. 71, nr. 5, 2009Nov. England. s. 652-8 / Plasma monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1alpha are 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. increased in patients with polycystic ovary syndrome (PCOS) and associated with adiposity, but unaffected by pioglitazone treatment. Glintborg, Dorte ; Andersen, Marianne. I: ved ikke. 2009 / Medicinske sygdomme og tilstande med relevans for tandlægens kliniske hverdag. Hypofyse- og binyresygdomme. Gulmez, Sinem Ezgi ; Lassen, Annmarie Touborg ; Aalykke, Claus ; Dall, Michael ; Andries, Alin ; Andersen, Birthe Søgaard ; Hansen, Jane Møller ; Andersen, Morten ; Hallas, Jesper. I: British Journal of Clinical Pharmacology. 2009 ; vol. 67, nr. 4, 2009-Apr. England. s. 460-5 / Do statins protect against upper gastrointestinal bleeding? Grau, K ; Hansen, Torben ; Holst, C ; Astrup, A ; Saris, W H M ; Arner, P ; Rössner, S ; Macdonald, I ; Polak, J ; Oppert, J-M ; Langin, D ; Martinez, J A ; Pedersen, O ; Sørensen, T I A. I: International Journal of Obesity. 2009 ; vol. 33, nr. 11, 2009-Nov. England. s. 1227-34 / Macronutrient-specific effect of FTO rs9939609 in response to a 10-week randomized hypo-energetic diet among obese Europeans. Grunnet, Louise G ; Brøns, Charlotte ; Jacobsen, Stine ; Nilsson, Emma ; Astrup, Arne ; Hansen, Torben ; Pedersen, Oluf ; Poulsen, Pernille ; Quistorff, Bjørn ; Vaag, Allan. I: Journal of Clinical Endocrinology and Metabolism. 2009 ; vol. 94, nr. 2, 2009-Feb. United States. s. 596-602 / Increased recovery rates of phosphocreatine and inorganic phosphate after isometric contraction in oxidative muscle fibers and elevated hepatic insulin resistance in homozygous carriers of the A-allele of FTO rs9939609. Grunnet, Louise G ; Nilsson, Emma ; Ling, Charlotte ; Hansen, Torben ; Pedersen, Oluf ; Groop, Leif ; Vaag, Allan ; Poulsen, Pernille. I: Diabetes. 2009 ; vol. 58, nr. 10, 2009-Oct. United States. s. 24028 / Regulation and function of FTO mRNA expression in human skeletal muscle and subcutaneous adipose tissue. Hansen, S J ; Nielsen, Morten M. ; Ryg, J ; Wraae, K ; Andersen, Marianne ; Brixen, K. I: Acta Radiologica. 2009 ; vol. 50, nr. 6, 2009-Jun-1. s. 658-63 / Radiographic Absorptiometry as a Screening Tool in Male Osteoporosis : Results from the Odense Androgen Study. Hald, Andreas ; Hansen, RR ; Thomsen, MW ; Ding, Ming ; Croucher, PI ; Gallagher, O ; Ebetino, FH ; Kassem, Moustapha ; Heegaard, AM. I: International Journal of Cancer. 2009 ; vol. 125, nr. 5, 2009 Mar 19. s. 1177-1185 / Cancer-induced bone loss and associated pain-related behavior is reduced by risedronate but not its phosphonocarboxylate analog NE-10790 Heile, Anna M B ; Wallrapp, Christine ; Klinge, Petra M ; Samii, Amir ; Kassem, Moustapha ; Silverberg, Gerald ; Brinker, Thomas. I: Neuroscience letters. 2009 ; vol. 463, nr. 3, 2009-Oct-9. Ireland. s. 176-81 / Cerebral transplantation of encapsulated mesenchymal stem cells improves cellular pathology after experimental traumatic brain injury. Hegedüs, Laszlo ; Brix, Thomas H ; Paschke, Ralf. I: Thyroid. 2009 ; vol. 19, nr. 3, 2009-Mar. United States. s. 209-11 / Etiology of simple goiter. Hegedüs, Laszlo. I: Endocrinology & Metabolism Clinics of North America. 2009 ; vol. 38, nr. 2, 2009-Jun. United States. s. 355-71, ix / Treatment of Graves’ hyperthyroidism: evidence-based and emerging modalities. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 26 Henriksen, Kim ; Byrjalsen, Inger ; Nielsen, Rasmus H ; Madsen, Andreas N ; Larsen, Leif K ; Christiansen, Claus ; Beck-Nielsen, Henning ; Karsdal, Morten A. I: European Journal of Pharmacology. 2009 ; vol. 616, nr. 1-3, 2009-Aug-15. Netherlands. s. 340-5 / A comparison of glycemic control, water retention, and musculoskeletal effects of balaglitazone and pioglitazone in diet-induced obese rats. Holmkvist, Johan ; Banasik, Karina ; Andersen, Gitte ; Unoki, Hiroyuki ; Jensen, Thomas Skot ; Pisinger, Charlotta ; Borch-Johnsen, Knut ; Sandbaek, Annelli ; Lauritzen, Torsten ; Brunak, Sören ; Maeda, Shiro ; Hansen, Torben ; Pedersen, Oluf. I: PLoS ONE. 2009 ; vol. 4, nr. 6, 2009-null. United States. s. e5872 / The type 2 diabetes associated minor allele of rs2237895 KCNQ1 associates with reduced insulin release following an oral glucose load Home, Philip D ; Pocock, Stuart J ; Beck-Nielsen, Henning ; Curtis, Paula S ; Gomis, Ramon ; Hanefeld, Markolf ; Jones, Nigel P ; Komajda, Michel ; McMurray, John J V ; RECORD Study Team. I: Lancet. 2009 ; vol. 373, nr. 9681, 2009-Jun-20. England. s. 212535 / Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Højlund, Kurt ; Birk, Jesper B ; Klein, Ditte K ; Levin, Klaus ; Rose, Adam J ; Hansen, Bo F ; Nielsen, Jakob N ; Beck-Nielsen, Henning ; Wojtaszewski, Jørgen F P. I: Journal of Clinical Endocrinology and Metabolism. 2009 ; vol. 94, nr. 11, 2009-Nov. United States. s. 4547-56 / Dysregulation of glycogen synthase COOH- and NH2terminal phosphorylation by insulin in obesity and type 2 diabetes mellitus. Højlund, Kurt ; Birk, Jesper B ; Klein, Ditte K ; Levin, Klaus ; Rose, Adam J ; Hansen, Bo F ; Nielsen, Jakob N ; Beck-Nielsen, Henning ; Wojtaszewski, Jørgen F P. I: Journal of Clinical Endocrinology and Metabolism. 2009 ; vol. 94, nr. 11, 2009-Nov. United States. s. 4547-56 / Dysregulation of glycogen synthase COOH- and NH2terminal phosphorylation by insulin in obesity and type 2 diabetes mellitus. / Forskning: Højlund, Kurt ; Bowen, Benjamin P ; Hwang, Hyonson ; Flynn, Charles R ; Madireddy, Lohith ; Thangiah, Geetha ; Meyer, Christian ; Mandarino, Lawrence J ; Yi, Zhengping. I: Journal of Proteome Research. 2009 ; vol. 8, nr. 11, 2009-Sep-18. s. 4954-65 / In vivo Phosphoproteome of Human Skeletal Muscle Revealed by Phosphopeptide Enrichment and HPLC-ESI-MS/MS. Ibsen, Hans ; Jørgensen, Torben ; Jensen, Gorm B ; Jacobsen, Ib Abildgaard. I: Ugeskrift for læger. 2009 ; vol. 171, nr. 24, 2009-Jun8. Denmark. s. 1998-2000 / Hypertension--forekomst og behandling. Jacobsen, Iben Brock ; Henriksen, J E ; Hother-Nielsen, O ; Vach, W ; Beck-Nielsen, H. I: Diabetes Research and Clinical Practice. 2009 ; vol. 86, nr. 1, 2009-Oct. Ireland. s. 1-10 / Evidence-based insulin treatment in type 1 diabetes mellitus. Jacobsen, Iben Brock ; Henriksen, Jan Erik ; Beck-Nielsen, Henning. I: Basic & Clinical Pharmacology & Toxicology. 2009 ; vol. 105, nr. 3, 2009-Sep. Denmark. s. 145-9 / The effect of metformin in overweight patients with type 1 diabetes and poor metabolic control. Jensen, Thomas ; Dolatshahi-Pirouz, Alireza ; Foss, Morten ; Baas, Jørgen ; Lovmand, Jette ; Duch, Mogens ; Pedersen, Finn Skou ; 57. 58. 59. 60. 61. 62. 63. 64. 65. Kassem, Moustapha ; Bünger, Cody ; Søballe, Kjeld ; Besenbacher, Flemming. I: Colloids and surfaces. B, Biointerfaces. 2009 ; vol. 75, nr. 1, 2010-Jan-1. Netherlands. s. 186-93 / Interaction of human mesenchymal stem cells with osteopontin coated hydroxyapatite surfaces. Jensen, Dorte M ; Damm, Peter ; Ovesen, Per ; Mølsted-Pedersen, Lars ; Beck-Nielsen, Henning ; Westergaard, Jes G ; Moeller, Margrethe ; Mathiesen, Elisabeth R. I: Diabetes Care. 2009 ; vol. 33, nr. 1, 2010-Jan. United States. s. 90-4 / Microalbuminuria, preeclampsia, and preterm delivery in pregnant women with type 1 diabetes: results from a nationwide Danish study. Jensen, Dorte M ; Korsholm, Lars ; Ovesen, Per ; Beck-Nielsen, Henning ; Moelsted-Pedersen, Lars ; Westergaard, Jes G ; Møller, Margrethe ; Damm, Peter. I: Diabetes Care. 2009 ; vol. 32, nr. 6, 2009-June. s. 1046-1048 / Peri-conceptional HbA1c and risk of serious adverse pregnancy outcome in 933 women with type 1 diabetes. Jägerström, Sara ; Polesie, Sam ; Wickström, Ylva ; Johansson, Bengt R ; Schröder, Henrik D ; Højlund, Kurt ; Boström, Pontus. I: Cell Biology International. 2009 ; vol. 33, nr. 9, Sep. Netherlands. s. 934-40 / Lipid droplets interact with mitochondria using SNAP23. Jørgensen, Gitte Maria ; Vind, Birgitte ; Nybo, Mads ; Rasmussen, Lars Melholt ; Højlund, Kurt. I: European Journal of Endocrinology. 2009 ; vol. 161, nr. 1, 2009-Jul. England. s. 95-101 / Acute hyperinsulinemia decreases plasma osteoprotegerin with diminished effect in type 2 diabetes and obesity. Karsdal, M A ; Henriksen, K ; Leeming, D J ; Mitchell, P ; Duffin, K ; Barascuk, N ; Klickstein, L ; Aggarwal, P ; Nemirovskiy, O ; Byrjalsen, I ; Qvist, P ; Bay-Jensen, A C ; Dam, E B ; Madsen, S H ; Christiansen, C. I: Biomarkers. 2009 ; vol. 14, nr. 3, 2009-May. England. s. 181-202 / Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Kjaerskov, Mette Wanscher ; Comstedt, Lisbeth Rosholm ; Bygum, Anette ; Yderstraede, Knud Bonnet. I: Ugeskrift for læger. 2009 ; vol. 171, nr. 22, 2009-May-25. Denmark. s. 1864-5 / Penil kalcifylaksi. Koutnikova, Hana ; Laakso, Markku ; Lu, Lu ; Combe, Roy ; Paananen, Jussi ; Kuulasmaa, Teemu ; Kuusisto, Johanna ; Häring, HansUlrich ; Hansen, Torben ; Pedersen, Oluf ; Smith, Ulf ; Hanefeld, Markolf ; Williams, Robert W ; Auwerx, Johan. I: PLoS Genetics. 2009 ; vol. 5, nr. 8, 2009-Aug. United States. s. e1000591 / Development of a type 2 diabetes risk model from a panel of serum biomarkers from the Inter99 cohort. Identification of the UBP1 locus as a critical blood pressure determinant using a combination of mouse and human genetics. Kring, Sofia I I ; Werge, Thomas ; Holst, Claus ; Toubro, Søren ; Astrup, Arne ; Hansen, Torben ; Pedersen, Oluf ; Sørensen, Thorkild I A. I: PLoS ONE. 2009 ; vol. 4, nr. 8, 2009-null. United States. s. e6696 / Polymorphisms of serotonin receptor 2A and 2C genes and COMT in relation to obesity and type 2 diabetes. Kristensen, Ida Bruun ; Møller, Hanne ; Kjaerskov, Mette Wanscher ; Yderstraede, Knud ; Møller, Michael Boe ; Bergmann, Olav J. I: Acta Dermato Venereologica. 2009 ; vol. 89, nr. 2, 2009-null. Sweden. s. 175-7 7 Myeloid sarcoma developing in pre-existing pyoderma gangrenosum. 27 66. 67. 68. 69. 70. 71. 72. 73. 74. 75. 76. Kronborg, CN ; Hallas, J ; Jacobsen, Ib Abildgaard. I: American Journal of Hypertension. 2009 ; vol. 3, nr. 1, s. 19-24 / Prevalence, wawreness and control of arterial hypertension in Denmark. Lauenborg, Jeannet ; Grarup, Niels ; Damm, Peter ; Borch-Johnsen, Knut ; Jørgensen, Torben ; Pedersen, Oluf ; Hansen, Torben. I: Journal of Clinical Endocrinology and Metabolism. 2009 ; vol. 94, nr. 1, 2009-Jan. United States. s. 145-50 / Common type 2 diabetes risk gene variants associate with gestational diabetes. Lauridsen, Mette Høj ; Boesgaard, Trine Welløv ; Pedersen, Oluf Borbye ; Hansen, Torben ; Hertz, Birgitte. I: Ugeskrift for læger. 2009 ; vol. 171, nr. 23, 2009-Jun-1. Denmark. s. 1923-4 / Spædbørnsdiabetes kan ofte behandles med sulfonylurinstof i stedet for insulin. Lefort, Natalie ; Yi, Zhengping ; Bowen, Benjamin ; Glancy, Brian ; De Filippis, Eleanna A ; Mapes, Rebekka ; Hwang, Hyonson ; Flynn, Charles R ; Willis, Wayne T ; Civitarese, Anthony ; Højlund, Kurt ; Mandarino, Lawrence J. I: Journal of Proteomics. 2009 ; vol. 72, nr. 6, Aug-20. Netherlands. s. 1046-60 / Proteome profile of functional mitochondria from human skeletal muscle using onedimensional gel electrophoresis and HPLC-ESI-MS/MS. Liedert, Astrid ; Kassem, Moustapha ; Claes, Lutz ; Ignatius, Anita. I: Biochemical and Biophysical Research Communications. 2009 ; vol. 387, nr. 2, 2009-Sep-18. United States. s. 289-93 / Mechanosensitive promoter region in the human HB-GAM gene Madsen, S H ; Sondergaard, B C ; Jensen, Anne-Christine Bay ; Karsdal, M A. I: Scandinavian Journal of Rheumatology. 2009 ; vol. 38, nr. 3, Norway. s. 222-6 / Cartilage formation measured by a novel PIINP assay suggests that IGF-I does not stimulate but maintains cartilage formation ex vivo. Madsen, Ida Ringsborg ; Hørder, Kirsten ; Støving, René Klinkby. I: Journal of Psychosomatic Obstetrics and Gynaecology. 2009 ; vol. 30, nr. 2, Jun. England. s. 122-6 / Remission of eating disorder during pregnancy : five cases and brief clinical review. Mercader, Josep ; Ribot, Joan ; Murano, Incoronata ; Feddersen, Søren ; Cinti, Saverio ; Madsen, Lise ; Kristiansen, Karsten ; Bonet, M Luisa ; Palou, Andreu. I: American Journal of Physiology: Endocrinology and Metabolism. 2009 ; vol. 297, nr. 1, 2009-Jul. United States. s. E184-93 / Haploinsufficiency of the retinoblastoma protein gene reduces diet-induced obesity, insulin resistance, and hepatosteatosis in mice. Mogensen, M ; Vind, B F ; Højlund, K ; Beck-Nielsen, H ; Sahlin, K. I: Diabetes, Obesity and Metabolism. 2009 ; vol. 11, nr. 9, Sep. England. s. 874-83 / Maximal lipid oxidation in patients with type 2 diabetes is normal and shows an adequate increase in response to aerobic training. Mosekilde, Leif ; Brixen, Kim ; Jespersen, Bente ; Kassem, Moustapha ; Vestergaard, Peter. I: Medicinsk kompendium. / red. Ove B Schaffalitzky de Muckadell ; Stig Haunsø ; Hendrik Vildstrup. Bd. 2 17. udg. Nyt Nordisk Forlag / Schønberg Forlag / Arnold Busck, 2009. s. 2247-2333 / Calciummetaboliske sygdomme og forstyrrelser i fosfat- og magnesiumstofskiftet. Muscelli, Elza ; Kozàkovà, Michaela ; Flyvbjerg, Allan ; Kyriakopoulou, Konstantina ; Astiarraga, Brenno D ; Glintborg, Dorte ; Konrad, Thomas ; Favuzzi, Angela ; Petrie, Jhon ; RISC investigators. I: American Journal of Hypertension. 2009 ; vol. 22, nr. 4, 2009-Apr. United States. s. 364-70 / The effect of menopause on carotid artery remodeling, insulin sensitivity, and plasma adiponectin in healthy women. 77. 78. 79. 80. 81. 82. 83. 84. 85. 86. 87. Nehlin, Jan ; Barington, Torben. I: Biogerontology. 2009 ; vol. 10, nr. 4, 2009-Aug. Netherlands. s. 339-76 / Strategies for future histo compatible stem cell therapy. Nielsen, Jacob F ; El Fassi, Daniel ; Nielsen, Claus H ; Hegedüs, Laszlo ; Lauer, Simeon A ; Silkiss, Rona Z ; Prause, Jan U. I: Acta Ophthamologica (Online). 2009 ; vol. 87, nr. 8, 2009-Nov. England. s. 927-9 / Evidence of orbital B and T cell depletion after rituximab therapy in Graves’ ophthalmopathy. Nielsen, Claus H ; Brix, Thomas H ; Leslie, R Graham Q ; Hegedüs, Laszlo. I: Clinical Immunology. 2009 ; vol. 133, nr. 2, 2009-Nov. United States. s. 218-27 / A role for autoantibodies in enhancement of pro-inflammatory cytokine responses to a self-antigen, thyroid peroxidase. Nielsen, Jacob F ; El Fassi, Daniel ; Nielsen, Claus H ; Hegedüs, Laszlo ; Lauer, Simeon A ; Silkiss, Rona Z ; Prause, Jan U. I: Acta Ophthamologica (Online). 2009 ; vol. 87, nr. 8, 2009-Nov. England. s. 927-9 / Evidence of orbital B and T cell depletion after rituximab therapy in Graves’ ophthalmopathy. Nissen, Nis ; Madsen, Jonna Skov ; Bladbjerg, Else-Marie ; Beck Jensen, J E ; Jørgensen, N R ; Langdahl, B ; Abrahamsen, B ; Brixen, Kim. I: Calcified Tissue International. 2009 ; vol. 84, nr. 4, 2009Apr. United States. s. 276-85 /No association between hip geometry and four common polymorphisms associated with fracture : the Danish osteoporosis prevention study. Pedersen, Oluf; Beck-Nielsen, Henning, Poulsen, Mandrup Thomas, Flyvbjerg, A. I: Medicinsk kompendium. / red. Ove B Schaffalitzky de Muckadell ; Stig Haunsø ; Hendrik Vildstrup. Bd. 2 17. udg. Nyt Nordisk Forlag / Schønberg Forlag / Arnold Busck, 2009. s. 2389-2392 / Diabetes Mellitus/Hypoglycæmi Pilgaard, K ; Jensen, C B ; Schou, J H ; Lyssenko, V ; Wegner, L ; Brøns, C ; Vilsbøll, T ; Madsbad, S ; Holst, J J ; Vølund, A ; Poulsen, P ; Groop, L ; Pedersen, O ; Hansen, Torben ; Vaag, A A. I: Diabetologia. 2009 ; vol. 52, nr. 7, 2009-Jul. Germany. s. 1298-307 / The T allele of rs7903146 TCF7L2 is associated with impaired insulinotropic action of incretin hormones, reduced 24 h profiles of plasma insulin and glucagon, and increased hepatic glucose production in young healthy men. Poulsen, Mikael ; Henriksen, Jan ; Dahl, Jordi ; Johansen, Allan ; Møller, Jacob ; Gerke, Oke ; Vach, Werner ; Haghfelt, Torben ; Beck-Nielsen, Henning ; Høilund-Carlsen, Poul. I: Journal of Nuclear Cardiology. 2009 ; vol. 16, nr. 6, s. 878-887 / Myocardial ischemia, carotid, and peripheral arterial disease and their interrelationship in type 2 diabetes patients. Poulsen, Pernille ; Grunnet, Louise G ; Pilgaard, Kasper ; Storgaard, Heidi ; Alibegovic, Amra ; Sonne, Mette P ; Carstensen, Bendix ; Beck-Nielsen, Henning ; Vaag, Allan. I: Diabetes. 2009 ; vol. 58, nr. 6, June. s. 1350-1355 / Increased risk of Type 2 diabetes in Elderly Twins. Prokhorova, Tatyana A ; Rigbolt, Kristoffer T G ; Johansen, Pia T ; Henningsen, Jeanette ; Kratchmarova, Irina ; Kassem, Moustapha ; Blagoev, Blagoy. I: Molecular and Cellular Proteomics. 2009 ; vol. 8, nr. 5, May. United States. s. 959-70 7 Stable isotope labeling by amino acids in cell culture (SILAC) and quantitative comparison of the membrane proteomes of self-renewing and differentiating hu man embryonic stem cells. Radha, V ; Ek, J ; Anuradha, S ; Hansen, Torben ; Pedersen, O ; Mohan, V. I: Journal of Clinical Endocrinology and Metabolism. 2009 ; vol. 94, nr. 6, 2009-Jun. United States. s. 1959-65 / Identifi- 88. 89. 90. 91. 92. 93. 94. 28 cation of novel variants in the hepatocyte nuclear factor-1alpha gene in South Indian patients with maturity onset diabetes of young. Rathcke, Camilla Noelle ; Holmkvist, Johan ; Jørgensen, Torben ; Borch-Johnsen, Knut ; Hansen, Torben ; Pedersen, Oluf Borbye ; Vestergaard, Henrik. I: PLoS ONE. 2009 ; vol. 4, nr. 5, 2009-null. United States. s. e5469 / Variation in CHI3LI in relation to type 2 diabetes and related quantitative traits. Reiling, Erwin ; van Vliet-Ostaptchouk, Jana V ; van ‘t Riet, Esther ; van Haeften, Timon W ; Arp, Pascal A ; Hansen, Torben ; Kremer, Dennis ; Groenewoud, Marlous J ; van Hove, Els C ; Romijn, Johannes A ; Smit, Jan W A ; Nijpels, Giel ; Heine, Robert J ; Uitterlinden, André G ; Pedersen, Oluf ; Slagboom, P Eline ; Maassen, Johannes A ; Hofker, Marten H ; ‘t Hart, Leen M ; Dekker, Jacqueline M. I: European Journal of Human Genetics. 2009 ; vol. 17, nr. 8, 2009-Aug. England. s. 1056-62 / Genetic association analysis of 13 nuclear-encoded mitochondrial candidate genes with type II diabetes mellitus: the DAMAGE study. Richardot, P ; Charni-Ben Tabassi, N ; Toh, L ; Marotte, H ; Jensen, Anne-Christine Bay ; Miossec, P ; Garnero, P. I: Osteoarthritis and Cartilage. 2009 ; vol. 17, nr. 10, 2009-Oct. England. s. 1362-/ Nitrated type III collagen as a biological marker of nitric oxide-mediated synovial tissue metabolism in osteoarthritis. Rose, C S ; Grarup, N ; Krarup, N T ; Poulsen, P ; Wegner, L ; Nielsen, T ; Banasik, K ; Faerch, K ; Andersen, G ; Albrechtsen, A ; Borch-Johnsen, K ; Clausen, J O ; Jørgensen, T ; Vaag, A ; Pedersen, O ; Hansen, Torben. I: Diabetologia. 2009 ; vol. 52, nr. 10, 2009Oct. Germany. s. 2122-9 / A variant in the G6PC2/ABCB11 locus is associated with increased fasting plasma glucose, increased basal hepatic glucose production and increased insulin release after oral and intravenous glucose loads. de Rooij, Susanne R ; Dekker, Jacqueline M ; Kozakova, Michaela ; Mitrakou, Asimina ; Melander, Olle ; Gabriel, Rafael ; Guidone, Caterina ; Højlund, Kurt ; Murphy, Matthew S ; Nijpels, Giel ; RISC Group Investigators. I: European Journal of Endocrinology. 2009 ; vol. 161, nr. 2, 2009-Aug. England. s. 223-30 / Fasting insulin has a stronger association with an adverse cardiometabolic risk profile than insulin resistance: the RISC study. Rung, Johan ; Cauchi, Stéphane ; Albrechtsen, Anders ; Shen, Lishuang ; Rocheleau, Ghislain ; Cavalcanti-Proença, Christine ; Bacot, François ; Balkau, Beverley ; Belisle, Alexandre ; Borch-Johnsen, Knut ; Charpentier, Guillaume ; Dina, Christian ; Durand, Emmanuelle ; Elliott, Paul ; Hadjadj, Samy ; Järvelin, Marjo-Riitta ; Laitinen, Jaana ; Lauritzen, Torsten ; Marre, Michel ; Mazur, Alexander ; Meyre, David ; Montpetit, Alexandre ; Pisinger, Charlotta ; Posner, Barry ; Poulsen, Pernille ; Pouta, Anneli ; Prentki, Marc ; Ribel-Madsen, Rasmus ; Ruokonen, Aimo ; Sandbaek, Anelli ; Serre, David ; Tichet, Jean ; Vaxillaire, Martine ; Wojtaszewski, Jørgen F P ; Vaag, Allan ; Hansen, Torben ; Polychronakos, Constantin ; Pedersen, Oluf ; Froguel, Philippe ; Sladek, Robert. I: Nature Genetics. 2009 ; vol. 41, nr. 10, 2009-Oct. United States. s. 1110-5 / Genetic variant near IRS1 is associated with type 2 diabetes, insulin resistance and hyperinsulinemia. Ryg, Jesper ; Rejnmark, Lars ; Overgaard, Soren ; Brixen, Kim ; Vestergaard, Peter. I: Journal of Bone and Mineral Research. 2009 ; vol. 24, nr. 7, July. s. 1299-1307 / Hip Fracture Patients at Risk of Second Hip Fracture-A Nationwide Population-Based Cohort Study of 169,145 Cases During 1977-2001. 95. Salanti, Georgia ; Southam, Lorraine ; Altshuler, David ; Ardlie, Kristin ; Barroso, Inês ; Boehnke, Michael ; Cornelis, Marilyn C ; Frayling, Timothy M ; Grallert, Harald ; Grarup, Niels ; Groop, Leif ; Hansen, Torben ; Hattersley, Andrew T ; Hu, Frank B ; Hveem, Kristian ; Illig, Thomas ; Kuusisto, Johanna ; Laakso, Markku ; Lan genberg, Claudia ; Lyssenko, Valeriya ; McCarthy, Mark I ; Morris, Andrew ; Morris, Andrew D ; Palmer, Colin N A ; Payne, Felicity ; Platou, Carl G P ; Scott, Laura J ; Voight, Benjamin F ; Wareham, Nicholas J ; Zeggini, Eleftheria ; Ioannidis, John P A. I: American Journal of Epidemiology. 2009 ; vol. 170, nr. 5, 2009-Sep-1. United States. s. 537-45 / Underlying genetic models of inheritance in established type 2 diabetes associations. 96. Scheller, Rudolf Albert ; Bygum, Anette ; Brixen, Kim ; Brøndum Nielsen, Karen. I: Investigative Ophthalmology & Visual Science. 2009 ; vol. 50, nr. 3, 03-2009. s. 1058-1064 / Birth prevalence and mutation spectrum in danish patients with autosomal recessive albi nism. 97. Sparsø, T ; Grarup, N ; Andreasen, C ; Albrechtsen, A ; Holmkvist, J ; Andersen, G ; Jørgensen, T ; Borch-Johnsen, K ; Sandbaek, A ; Lauritzen, T ; Madsbad, S ; Hansen, Torben ; Pedersen, O. I: Dia betologia. 2009 ; vol. 52, nr. 7, 2009-Jul. Germany. s. 1308-14 / Combined analysis of 19 common validated type 2 diabetes su sceptibility gene variants shows moderate discriminative value and no evidence of gene-gene interaction. 98. Sparsø, Thomas ; Bonnefond, Amélie ; Andersson, Ehm ; Bouatia Naji, Nabila ; Holmkvist, Johan ; Wegner, Lise ; Grarup, Niels ; Gjesing, Anette P ; Banasik, Karina ; Cavalcanti-Proença, Christi ne ; Marchand, Marion ; Vaxillaire, Martine ; Charpentier, Guil laume ; Jarvelin, Marjo-Riitta ; Tichet, Jean ; Balkau, Beverley ; Marre, Michel ; Lévy-Marchal, Claire ; Faerch, Kristine ; Borch Johnsen, Knut ; Jørgensen, Torben ; Madsbad, Sten ; Poulsen, Per nille ; Vaag, Allan ; Dina, Christian ; Hansen, Torben ; Pedersen, Oluf ; Froguel, Philippe. I: Diabetes. 2009 ; vol. 58, nr. 6, 2009-Jun. United States. s. 1450-6 / G-allele of intronic rs10830963 in MT NR1B confers increased risk of impaired fasting glycemia and type 2 diabetes through an impaired glucose-stimulated insulin release: studies involving 19,605 Europeans. 99. Thingholm, Tine E ; Jensen, Ole N ; Larsen, Martin R. I: Proteo mics. 2009 ; vol. 9, nr. 6, 2009-Mar. Germany. s. 1451-1468 / Ana lytical strategies for phosphoproteomics. 100.Thingholm, Tine E ; Larsen, Martin R. I: Methods in Molecular Biology. 2009 ; vol. 527, 2009-null. United States. s. 57-66 / The use of titanium dioxide micro-columns to selectively isolate phos phopeptides from proteolytic digests. 101.Vad Winkler, Laura ; Andersen, Marianne ; Hørder, Kirsten ; Schu mann, Thorsten ; Støving, René Klinkby. I: International Journal of Eating Disorders. 2009 ; vol. 42, nr. 5, July. s. 475-478 / Slow-gro wing craniopharyngioma masquarading as early-onset eating disor der: Two cases. 102.Wang, Bijue ; Chen, Pingping ; Jensen, Anne-Christine Bay ; Kars dal, Morten A ; Madsen, Suzi H ; Sondergaard, Bodil-Cecilie ; Zheng, Qinlong ; Qvist, Per. I: B M C Research Notes. 2009 ; vol. 2, 2009-null. England. s. 259 / Suppression of MMP activity in bo vine cartilage explants cultures has little if any effect on the release of aggrecanase-derived aggrecan fragments. 103.Wedderkopp, Niels ; Kjaer, P ; Hestbaek, L ; Korsholm, L ; Leboeuf Yde, C. I: Spine Journal. 2009 ; vol. 9, nr. 2, s. 134-141 / High-level physical activity in childhood seems to protect against low back pain in early adolescence. 104.Watt, Torquil ; Bjorner, Jakob Bue ; Groenvold, Mogens ; Rasmus sen, Ase Krogh ; Bonnema, Steen Joop ; Hegedüs, Laszlo ; Feldt Rasmussen, Ulla. I: Quality of Life Research. 2009 ; vol. 18, nr. 4, 2009-May. Netherlands. s. 483-96 / Establishing construct validity for the thyroid-specific patient reported outcome measure (Thy PRO) : an initial examination. 105.Watt, Torquil ; Hegedüs, Laszlo ; Groenvold, Mogens ; Bjorner, Jakob Bue ; Rasmussen, Ase Krogh ; Bonnema, Steen Joop ; Feldt Rasmussen, Ulla. I: European Journal of Endocrinology. 2009 ; vol. 162, nr. 1, 2010-Jan. England. s. 161-7 / Validity and reliability of the novel thyroid-specific quality of life questionnaire, ThyPRO. 106.Xiao, X ; Wang, T ; Li, W ; Song, H ; Gong, C ; Diao, C ; Yu, M ; Yuan, T ; Zhang, Y ; Sun, X ; Zhang, Q ; Lu, K ; Wang, H ; Schmitz, O ; Hansen, Torben. I: Hormone and Metabolic Research. 2009 ; vol. 41, nr. 7, 2009-Jul. Germany. s. 580-2 / Transfer from insulin to sulfonylurea treatment in a chinese patient with permanent neo natal diabetes mellitus due to a KCNJ11 R201H mutation. 107.Yderstraede, Knud Bonnet ; Clemmensen, Ole ; Nielsen, Anna Ma rie ; Marckmann, Peter ; Bygum, Anette. I: Ugeskrift for læger. 2009 ; vol. 171, nr. 22, 2009-May-25. Denmark. s. 1860-4 / Kalci fylaksi. 108.Zimmermann, Esther ; Kring, Sofia I I ; Berentzen, Tina L ; Holst, Claus ; Pers, Tune H ; Hansen, Torben ; Pedersen, Oluf ; Sørensen, Thorkild I A ; Jess, Tine. I: PLoS ONE. 2009 ; vol. 4, nr. 2, 2009 null. United States. s. e4428 / Fatness-associated FTO gene variant increases mortality independent of fatness--in cohorts of Danish men. In the lab 29 FINANCIAL SUPPORT TO EFE FROM INSTITUTIONS AND FOUNDATIONS Agnes og Knut Mørks Fond T. Brix.................................................. 35.000 Dansk Sygeplejeråd A.H. Nyland .......................................... 44.500 Diabetesforeningen A.D. Pørneki.......................................... 250.000 Dir. Jakob madsens & Hustru Olga Madsens Fond D. Glintborg.......................................... T. Brix.................................................. Forskningsrådet for Sundhed og Sygdom M. Gaster (2007-2009)........................... H. Beck-Nielsen (2008-2010)................... K. Højlund (2009-2012).......................... Forsknings- og Innovationsstyrelsen H. Beck Nielsen (2006-2011)................... H. Beck Nielsen (2006-2009)................... H. Beck Nielsen (2009-2012)................... M Kassem............................................. Genzyme Cooperation L. Hegedüs ........................................... DKK Novo Nordisk Fonden K. Højlund (2009-2013).......................... 5.000.000 K. Højlund ............................................ 350.000 L. Hegedüs ........................................... 500.000 B. Abdallah........................................... 650.000 M. Gaster.............................................. 150.000 M.F. Nielsen .......................................... 300.000 Odense Universitetshospitals Forskningsråd S. Bonnema.......................................... 60.000 15.000 20.000 Odense Universitetshospitals Frie Forskningsmidler T. Brix.................................................. 60.000 1.391.850 1.546.500 1.791.474 Poul & Erna Sehested Hansens Fond A.D. Pørneki ......................................... 70.000 4.000.000 3.570.000 5.568.750 146.918 Teknologisk Institut M. Kassem............................................ 1.196.000 200.000 Region Syddanmarks Forskningspulje I. Abildgaard......................................... 2.500.000 M.F. Nielsen .......................................... 606.000 Det Strategiske Forskningsråd M. Kassem............................................ 14.800.000 Thyroidealandspatientforeningen S. Bonnema.......................................... Lundbeckfonden M. Kassem............................................ 1.399.000 Diverse kommercielle Studier................. Dietician at work 30 40.000 8.458.403 31 The Bone and Calcium Research Unit Kim Brixen, Professor, Consultant, DMSc [email protected] Tel: +45 6541 4363 The Diabetes Research Unit Henning Beck-Nielsen, Professor, DMSc, Head of Research, Consultant [email protected] Tel.: +45 6541 3444 The Pituitary- and Clinical Nutrition Unit Marianne Andersen, PhD, Consultant [email protected] Tel.: +45 6541 3420 Rene Klinkby Støving, PhD, Consultant [email protected] Tel.: +45 6541 3378 The Thyroid Research Unit Laszlo Hegedüs, DMSc, Professor, Consultant [email protected] Tel.:+45 6541 3426 The Molecular Endocrinology Unit Moustapha Kassem, Professor, DMSc, Consultant [email protected] Tel.: +45 6541 1606 University of Southern Denmark Faculty of Health Science Winsløvparken 19, 3 DK- 5000 Odense C [email protected] Tel.: +45 6550 3018 Layout: Anne Christrup Odense University Hospital All units are situated at Kløvervænget 6 DK- 5000 Odense C